<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">100797</article-id><article-id pub-id-type="doi">10.7554/eLife.100797</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.100797.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Stem Cells and Regenerative Medicine</subject></subj-group></article-categories><title-group><article-title>GATA6 regulates WNT and BMP programs to pattern precardiac mesoderm during the earliest stages of human cardiogenesis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bisson</surname><given-names>Joseph A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0006-3702-7882</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Gordillo</surname><given-names>Miriam</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Ritu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="pa1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>de Silva</surname><given-names>Neranjan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Ellen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Banks</surname><given-names>Kelly M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Zhong-Dong</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Kihyun</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="pa2">‡</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Dapeng</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Chung</surname><given-names>Wendy K</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Huangfu</surname><given-names>Danwei</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Evans</surname><given-names>Todd</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7148-9849</contrib-id><email>tre2003@med.cornell.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02r109517</institution-id><institution>Department of Surgery, Weill Cornell Medicine</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02yrq0923</institution-id><institution>Developmental Biology Program, Sloan Kettering Institute</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vek6s52</institution-id><institution>Childrens Hospital, Harvard Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02r109517</institution-id><institution>Hartman Institute for Therapeutic Organ Regeneration, Weill Cornell Medicine</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02r109517</institution-id><institution>Center for Genomic Health, Weill Cornell Medicine</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Scott</surname><given-names>Ian C</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057q4rt57</institution-id><institution>The Hospital for Sick Children</institution></institution-wrap><country>Canada</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Stainier</surname><given-names>Didier YR</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0165r2y73</institution-id><institution>Max Planck Institute for Heart and Lung Research</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>Gladstone Institutes, San Francisco, United States</p></fn><fn fn-type="present-address" id="pa2"><label>‡</label><p>College of Pharmacy, Ewha Womans University, Seoul, South Korea</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>13</day><month>03</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP100797</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-07-09"><day>09</day><month>07</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-07-11"><day>11</day><month>07</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.07.09.602666"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-10-01"><day>01</day><month>10</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.100797.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-02-05"><day>05</day><month>02</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.100797.2"/></event></pub-history><permissions><copyright-statement>© 2024, Bisson et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Bisson et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-100797-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-100797-figures-v1.pdf"/><abstract><p>Haploinsufficiency for <italic>GATA6</italic> is associated with congenital heart disease (CHD) with variable comorbidity of pancreatic or diaphragm defects, although the etiology of disease is not well understood. Here, we used cardiac directed differentiation from human embryonic stem cells (hESCs) as a platform to study GATA6 function during early cardiogenesis. GATA6 loss-of-function hESCs had a profound impairment in cardiac progenitor cell (CPC) specification and cardiomyocyte (CM) generation due to early defects during the mesendoderm and lateral mesoderm patterning stages. Profiling by RNA-seq and CUT&amp;RUN identified genes of the WNT and BMP programs regulated by GATA6 during early mesoderm patterning. Furthermore, interactome analysis detected GATA6 binding with developmental transcription factors and chromatin remodelers, suggesting cooperative regulation of cardiac lineage gene accessibility. We show that modulating WNT and BMP inputs during the first 48 hr of cardiac differentiation is sufficient to partially rescue CPC and CM defects in <italic>GATA6</italic> heterozygous and homozygous mutant hESCs. This study provides evidence of the regulatory functions for GATA6 directing human precardiac mesoderm patterning during the earliest stages of cardiogenesis to further our understanding of haploinsufficiency causing CHD and the co-occurrence of cardiac and other organ defects caused by human <italic>GATA6</italic> mutations.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>Congenital heart disease results in babies being born with structural defects to their hearts. It is one of the most common kind of human birth defects, yet its genetic causes remain poorly understood. Previous studies have identified a gene known as <italic>GATA6</italic>, which is sometimes altered in patients with the condition. As for most human genes, cells typically carry two <italic>GATA6</italic> copies, each inherited from one parent. In many congenital heart disease patients, only one of the two copies of the gene presents harmful mutations. However, it has so far remained difficult to investigate in the laboratory how this genetic profile results in heart defects.</p><p>To bypass these limitations, Bisson et al. used human stem cells derived from the early embryo (known as hESCs) that can become any tissue in the body, including the heart. The team genetically designed hESC lines carrying either one (heterozygous) or two (homozygous) mutant copies of <italic>GATA6</italic>. Experiments showed that homozygous cells failed to generate any cardiac cells, while those stemming from heterozygous cells were partially impaired. Further molecular analyses established that <italic>GATA6</italic> acts early in development by regulating WNT and BMP, two signaling pathways that contribute to hESCs becoming heart cells.</p><p>These findings indicate that embryos in which both copies of GATA6 are defective cannot generate heart cells, and therefore are not viable. They also suggest that modulating WNT and BMP pathways early during development may partially rescue heart defects in mutant embryos. Overall, the work by Bisson et al. offers a promising avenue for future research into congenital heart disease by providing researchers with hESC lines in which GATA6 is mutated.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>heart development</kwd><kwd>congenital heart disease</kwd><kwd>cardiac progenitors</kwd><kwd>eomesodermin</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R35135778</award-id><principal-award-recipient><name><surname>Evans</surname><given-names>Todd</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01DK096239</award-id><principal-award-recipient><name><surname>Huangfu</surname><given-names>Danwei</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P01HD068250</award-id><principal-award-recipient><name><surname>Chung</surname><given-names>Wendy K</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>F32HL152575</award-id><principal-award-recipient><name><surname>Bisson</surname><given-names>Joseph A</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P30CA008748</award-id><principal-award-recipient><name><surname>Huangfu</surname><given-names>Danwei</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009784</institution-id><institution>Starr Foundation</institution></institution-wrap></funding-source><award-id>2016-004</award-id><principal-award-recipient><name><surname>Huangfu</surname><given-names>Danwei</given-names></name><name><surname>Evans</surname><given-names>Todd</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32GM007739</award-id><principal-award-recipient><name><surname>Banks</surname><given-names>Kelly M</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004857</institution-id><institution>New York State Department of Health - Wadsworth Center</institution></institution-wrap></funding-source><award-id>NYSTEM C029567</award-id><principal-award-recipient><name><surname>Huangfu</surname><given-names>Danwei</given-names></name><name><surname>Evans</surname><given-names>Todd</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Differentiation of human pluripotent stem cells mutant for one GATA6 gene can model developmental heart defects seen in some patients with congenital heart disease.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Congenital heart disease (CHD) is the most common human birth defect, affecting nearly 1% of live births (<xref ref-type="bibr" rid="bib23">Hoffman and Kaplan, 2002</xref>). CHD is generally understood to derive from dysfunction in the growth, morphogenesis, and/or differentiation of cardiac-fated progenitor cell derivatives; however, the genetic and molecular networks governing these processes remain under investigation. Treatment options are limited to surgical interventions that can save the life of the infant but do not correct the underlying genetics. The causative genetic variants may contribute to complications and morbidity in adulthood (<xref ref-type="bibr" rid="bib82">Woudstra et al., 2017</xref>). Research aimed to expand our understanding of the molecular genetics regulating normal human cardiogenesis is thus needed to advance therapeutic strategies in the detection and treatment of CHD.</p><p>Studies of cardiac development in model organisms have led to the discovery of key molecular drivers of heart organogenesis, including the GATA family of zinc-finger transcription factors. GATA factors, named by their ability to bind to the consensus sequence (<italic>A</italic>/<italic>T</italic>)<italic>GATA</italic>(<italic>A</italic>/<italic>G</italic>) (<xref ref-type="bibr" rid="bib48">Patient and McGhee, 2002</xref>), represent six family members with GATA4/5/6 expressed in the developing heart of early-stage embryos (<xref ref-type="bibr" rid="bib52">Peterkin et al., 2007</xref>; <xref ref-type="bibr" rid="bib43">Molkentin, 2000</xref>). GATA4/5/6 transcription factors regulate multiple stages of heart development including the specification, proliferation, and differentiation of cardiac progenitor cells (CPCs) (<xref ref-type="bibr" rid="bib51">Peterkin et al., 2005</xref>). Notably, <italic>GATA6</italic> knockout (KO) mice exhibit early embryonic arrest during primitive streak formation due to defects in visceral endoderm, a phenotype that has complicated the study of the early developmental function of GATA6 in vivo (<xref ref-type="bibr" rid="bib45">Morrisey et al., 1998</xref>). Mice with conditional deletion of <italic>GATA6</italic> from early CPCs develop heart abnormalities including atrioventricular canal defects, ventricular septal defects, and partial loss of trabeculae (<xref ref-type="bibr" rid="bib71">Tian et al., 2010</xref>; <xref ref-type="bibr" rid="bib78">van Berlo et al., 2010</xref>). While these <italic>GATA6</italic> conditional homozygous KO mice die at birth due to heart malformations, few cardiac phenotypes were reported in the <italic>GATA6</italic> heterozygous mutants, except for recent reports of bicuspid aortic valve and heart rhythm abnormalities (<xref ref-type="bibr" rid="bib16">Gharibeh et al., 2018</xref>; <xref ref-type="bibr" rid="bib17">Gharibeh et al., 2021</xref>).</p><p>In humans, heterozygous mutations in <italic>GATA6</italic> are associated with various forms of CHD including outflow tract (OFT) defects, septal defects, and Tetralogy of Fallot (<xref ref-type="bibr" rid="bib80">Wang et al., 2012</xref>; <xref ref-type="bibr" rid="bib86">Zhang et al., 2018</xref>). GATA6 is required for the development of multiple mesoderm and endoderm-derived organs, and some CHD patients with heterozygous <italic>GATA6</italic> mutations have comorbidities including pancreatic agenesis, neonatal diabetes, or congenital diaphragmatic hernia (<xref ref-type="bibr" rid="bib18">Gong et al., 2013</xref>; <xref ref-type="bibr" rid="bib85">Yu et al., 2014</xref>). The phenotypic diversity of birth defects in patients containing <italic>GATA6</italic> mutations illustrates the complexity of human haploinsufficiency; there is likely a combination of variants in modifying or interacting genes that converge to influence the disease phenotype (<xref ref-type="bibr" rid="bib12">Fahed et al., 2013</xref>; <xref ref-type="bibr" rid="bib57">Seidman and Seidman, 2002</xref>). Previous studies of the function of <italic>GATA6</italic> in model organisms have not sufficiently modeled the variety of cardiac (and noncardiac) defects observed in humans and most describe phenotypes only after homozygous inactivation of the gene. This raises an important question; why do CHDs in humans associate with <italic>GATA6</italic> haploinsufficiency? Species-specific functions for GATA6 may differ between mouse and humans, for example, raising the question of how observations made in model organisms relate to human cardiac development. There is a clear need to investigate the function of GATA6 in the context of a human system to better understand the basis for haploinsufficiency.</p><p>Current in vitro cardiac-directed differentiation protocols for human pluripotent stem cells (hPSCs) provide powerful tools for studying the transcriptional regulatory networks relevant to CHD (<xref ref-type="bibr" rid="bib46">Mummery et al., 2012</xref>). A previous study using human induced pluripotent stem cells (hiPSCs) with CRISPR-Cas9-induced <italic>GATA6</italic> mutations showed that GATA6 is required at the stages of CPC and cardiomyocyte (CM) differentiation (<xref ref-type="bibr" rid="bib58">Sharma et al., 2020</xref>). GATA6 is also required for definitive endoderm (DE) differentiation toward the pancreatic lineage as reported in several studies using hPSCs (<xref ref-type="bibr" rid="bib60">Shi et al., 2017</xref>; <xref ref-type="bibr" rid="bib21">Heslop et al., 2021</xref>; <xref ref-type="bibr" rid="bib6">Chia et al., 2019</xref>; <xref ref-type="bibr" rid="bib72">Tiyaboonchai et al., 2017</xref>). However, the function of GATA6 during early mesoderm patterning of human cardiac differentiation has not been explored, and how in vitro cardiac and DE lineage phenotypes caused by GATA6 loss-of-function relate to one another is not understood.</p><p>To determine the function of GATA6 during the earliest stages of cardiac differentiation, we performed in vitro CM-directed differentiation using <italic>GATA6</italic> loss-of-function human embryonic stem cell (hESC) lines and explored regulatory functions for GATA6 during precardiac mesoderm patterning that is ultimately required for CM generation. Transcriptome analysis revealed that <italic>GATA6</italic> mutations impaired expression of genes important for lateral and cardiac mesoderm patterning, and by integrating GATA6 CUT&amp;RUN sequencing with RNA-seq we identified GATA6-regulated targets including those of the WNT and BMP networks, key morphogenetic signaling pathways required to induce anterior primitive streak formation (<xref ref-type="bibr" rid="bib27">Ivanovitch et al., 2021</xref>; <xref ref-type="bibr" rid="bib14">Funa et al., 2015</xref>). Furthermore, we found that GATA6 interacts with important developmental transcription factors and chromatin remodelers during early mesoderm patterning stages that may promote DNA accessibility required for cardiac lineage commitment. Taken together, these findings uncover multiple functions for GATA6 in regulating very early precardiac mesoderm patterning and the lineage-specific gene networks required for human CM generation.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>GATA6 loss-of-function impairs cardiac mesoderm lineage differentiation</title><p>A monolayer cytokine-based in vitro cardiac differentiation protocol for hPSCs was adapted from previously established methods (<xref ref-type="bibr" rid="bib11">Dubois et al., 2011</xref>; <xref ref-type="bibr" rid="bib29">Kattman et al., 2011</xref>; <xref ref-type="bibr" rid="bib84">Yang et al., 2022</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>). <italic>GATA6</italic> heterozygous mutant (<italic>GATA6</italic><sup>+/-</sup>), homozygous mutant (<italic>GATA6</italic><sup>-/-</sup>), and isogenic wildtype (WT) control (<italic>GATA6</italic><sup>+/+</sup>) H1-hESC lines were previously generated (<xref ref-type="bibr" rid="bib60">Shi et al., 2017</xref>; <xref ref-type="bibr" rid="bib19">González et al., 2014</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A and B</xref>). These lines were differentiated in parallel to determine the impact of <italic>GATA6</italic> loss-of-function during human cardiogenesis. Western blotting at days 2 or 5 of cardiac differentiation confirmed the loss of GATA6 protein in <italic>GATA6</italic><sup>-/-</sup> cells and intermediate levels of protein in <italic>GATA6</italic><sup>+/-</sup> cells relative to WT controls (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). The percentage of cardiac troponin T-positive (%cTnT<sup>+</sup>) CMs in individual differentiation assays remained stable starting around day 13 and thus CM differentiation efficiency was analyzed during a window of days 13–18 of cardiac differentiation. <italic>GATA6</italic><sup>-/-</sup> cells failed to generate beating CMs and yielded close to 0% cTnT<sup>+</sup> CMs when examined by flow cytometry (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>). In contrast, <italic>GATA6</italic><sup>+/-</sup> hESCs did generate beating CMs (~25% cTnT<sup>+</sup>) but at a significantly reduced efficiency compared to WT cells (~55% cTnT<sup>+</sup>, <xref ref-type="fig" rid="fig1">Figure 1B and C</xref>). <italic>GATA6</italic><sup>+/-</sup> CMs obtained were comparable morphologically to WT CMs with no obvious sarcomere defects (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). No significant differences in %cTnT<sup>+</sup> were observed between clones of the same genotype (<xref ref-type="fig" rid="fig1">Figure 1C</xref>); therefore, data from lines with the same genotypes were combined in all subsequent comparisons.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>GATA6 loss-of-function inhibits cardiomyocyte (CM) and cardiac progenitor cell (CPC) development.</title><p>(<bold>A</bold>) Schematic for in vitro CM-directed differentiation cytokine-based protocol (used throughout the study except for <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B–E</xref>). Color gradients represent relative developmental stages (white: pluripotent; gray: mesoderm; yellow: cardiac mesoderm; pink: CPCs; and red: CMs). (<bold>B</bold>) Representative flow cytometry plots for cTnT<sup>+</sup> CMs at day 14 of cardiac differentiation for <italic>GATA6</italic><sup>+/+</sup>, <italic>GATA6</italic><sup>+/-</sup>, and <italic>GATA6</italic><sup>-/-</sup> hESCs. (<bold>C</bold>) %cTnT<sup>+</sup> CMs quantified by flow cytometry between days 13 and 16 (dots indicate independent biological replicates). Significance indicated as ****p&lt;0.0001 by two-way ANOVA with Tukey’s multiple-comparison test by genotype. There was no significant difference between clones of the same genotype when two-way ANOVA and Tukey’s multiple-comparison test were performed for all six sample groups. (<bold>D</bold>) Day 6 RT-qPCR for the CPC markers indicated normalized to <italic>GATA6</italic><sup>+/+</sup> (n = 6). (<bold>E</bold>) Day 6 RT-qPCR for heart field markers normalized to <italic>GATA6</italic><sup>+/+</sup> (n = 6). Data represents the mean ± SEM, significance indicated as *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns indicates not significant as determined by one-way ANOVA and Tukey’s multiple-comparison test. The labels w4, w2 (wildtype), m2, m5 (heterozygous), and m11, m14 (homozygous) refer to the isogenic wildtype and mutant hESC clones (see <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>).</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>cTnT flow cytometry in panel C.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-100797-fig1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>RT-qPCR in panels D and E.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-100797-fig1-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100797-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>CRISPR gene editing and characterization of mutant GATA6 human embryonic stem cell (hESC) and induced pluripotent stem cell (iPSC) lines.</title><p>(<bold>A</bold>) GATA6 CRISPR targeting scheme using H1 iCas9 hESCs is described in <xref ref-type="bibr" rid="bib60">Shi et al., 2017</xref>. Two CRISPR gRNAs were used targeting the C-terminal zinc finger domain (GATA6-Cr1 and Cr2 gRNA target sequence in green, red indicates the PAM). (<bold>B</bold>) Table describing H1-GATA6-hESC clonal lines, genotype designation, and gRNA used in gene editing. Predicted protein describes mutant alleles according to the Human Genome Variation Society (HGVS) guidelines, fs indicates frameshift mutation. (<bold>C</bold>) Western blots from <italic>GATA6</italic><sup>+/+</sup>, <italic>GATA6</italic><sup>+/-</sup>, and <italic>GATA6</italic><sup>-/-</sup> protein lysates at day 2 or 5 of cardiac differentiation probed for GATA6 with β-actin used as a loading control. (<bold>D</bold>) Immunofluorescence for the sarcomere marker α-actinin and co-stained with DAPI on day 23 lactate-purified cardiomyocytes (CMs). (<bold>E</bold>) Schematic for CRISPR-based correction of the GATA6 c.1071delG iPSC mutant allele to WT sequence (<italic>GATA6</italic><sup>corr/+</sup>). A pair of gRNAs flanking the G deletion site were used for targeting with Nickase-Cas9 and a WT repair template to allow for homology-directed repair (HDR) of the mutant allele. A single base substitution of G to A (indicated by brown) was used in the WT repair template to induce a silent mutation in the gRNA 2 recognition sequence to prevent additional Cas9 activity after HDR. (<bold>F</bold>) Table describing the GATA6 iPSC clonal lines. The GATA6 c.1071delG mutant allele is indicated as the protein V358Cfs (according to HGVS guidelines). (<bold>G</bold>) Immunofluorescence for the pluripotency markers NANOG or SOX2 on <italic>GATA6</italic><sup>corr/+</sup> or <italic>GATA6</italic><sup>1071delG/+</sup> iPSC colonies. (<bold>H</bold>) Flow cytometry quantification for %cTnT<sup>+</sup> CMs following cardiac directed differentiation for days 13–16 of <italic>GATA6</italic><sup>corr/+</sup> or <italic>GATA6</italic><sup>1071delG/+</sup> iPSCs. Data represents the mean ± SEM, dots represent independent biological replicates. Significance defined as **p&lt;0.01 using the two-tailed Student’s <italic>t</italic>-test. (<bold>I</bold>) Immunofluorescence for cTnT and co-stained with DAPI on day 23 lactate-purified iPSC-CMs. (<bold>J</bold>) Representative karyogram for <italic>GATA6</italic><sup>corr/+</sup> iPSCs. (<bold>K</bold>) Western blots from <italic>GATA6</italic><sup>corr/+</sup> or <italic>GATA6</italic><sup>1071delG/+</sup> protein lysates at day 5 of cardiac differentiation probed for GATA6 with β-actin used as a loading control.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Western blots in panels C and K.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-100797-fig1-figsupp1-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1—figure supplement 1—source data 2.</label><caption><title>cTnT flow cytometry in panel H.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-100797-fig1-figsupp1-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata3"><label>Figure 1—figure supplement 1—source data 3.</label><caption><title>Original unmarked western blot images in panel K.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100797-fig1-figsupp1-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100797-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Cardiac progenitor cell (CPC) marker gene transcriptional analysis of GATA6 WT or mutant human embryonic stem cells (hESCs).</title><p>(<bold>A</bold>) RT-qPCR time course for CPC markers (and <italic>GATA6</italic>) in differentiating <italic>GATA6</italic><sup>+/+</sup>, <italic>GATA6</italic><sup>+/-</sup>, and <italic>GATA6</italic><sup>-/-</sup> hESCs (normalized to day 2 WT gene expression levels). (<bold>B</bold>) Schematic for in vitro cardiomyocyte (CM)-directed differentiation CHIR protocol. (<bold>C</bold>) Principal component analysis (PCA) for comparisons of day 5 bulk RNA-seq from <italic>GATA6</italic><sup>+/+</sup>, <italic>GATA6</italic><sup>+/-</sup>, and <italic>GATA6</italic><sup>-/-</sup> hESCs using the CHIR protocol (n = 2). (<bold>D</bold>) Gene ontology (GO) analysis for biological process (BP) using differentially expressed genes (DEGs) from day 5 RNA-seq comparing <italic>GATA6</italic><sup>-/-</sup> to WT. (<bold>E</bold>) Heatmap for cardiac development related genes from day 5 RNA-seq. Color gradient indicates relative gene expression level. (<bold>F</bold>) RT-qPCR time course for <italic>ALDH1A2</italic> transcript levels in differentiating <italic>GATA6</italic><sup>+/+</sup>, <italic>GATA6</italic><sup>+/-</sup>, and <italic>GATA6</italic><sup>-/-</sup> hESCs using the cytokine-based protocol.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>RT-qPCR in panels A and F.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-100797-fig1-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100797-fig1-figsupp2-v1.tif"/></fig></fig-group><p>We also generated an iPSC line derived from a CHD patient presenting with an atrial septal defect and congenital diaphragmatic hernia; this patient was found to have a heterozygous frameshift mutation in <italic>GATA6</italic> (c.1071delG) (<xref ref-type="bibr" rid="bib85">Yu et al., 2014</xref>). The mutant allele was corrected to WT sequence (<italic>GATA6</italic><sup>corr/+</sup>) using CRISPR-Cas9 gene editing (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E and F</xref>). The iPSC colonies expressed normal levels of the pluripotency markers NANOG and SOX2 demonstrating efficient reprogramming (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1G</xref>). We performed cardiac differentiation using the cytokine-based protocol for <italic>GATA6</italic><sup>corr/+</sup> and <italic>GATA6</italic><sup>1071delG/+</sup> iPSCs to determine how the phenotype compared to the <italic>GATA6</italic><sup>+/+</sup> and <italic>GATA6</italic><sup>+/-</sup> H1-hESCs. To date, this is the first patient-derived iPSC line with a heterozygous <italic>GATA6</italic> mutation along with an isogenic mutation-corrected control to be evaluated for cardiac directed differentiation. <italic>GATA6</italic><sup>1071delG/+</sup> cells generated cTnT<sup>+</sup> CMs less efficiently than <italic>GATA6</italic><sup>corr/+</sup> cells, on average about 50% (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1H</xref>), indicating that the <italic>GATA6</italic> c.1071delG mutation similarly disrupts cardiac differentiation as observed in the hESC heterozygous mutant lines. Likewise, the CMs obtained by differentiation of either <italic>GATA6</italic><sup>1071delG/+</sup> or <italic>GATA6</italic><sup>corr/+</sup> iPSCs appeared morphologically normal (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1I</xref>). The fact that both types of heterozygous cells (patient-derived iPSCs and targeted H1-hESCs) generate similar defects in CM differentiation provides evidence supporting the use of the H1-hESCs and isogenic lines to study the genetic and cellular basis for CHD. The corrected iPSC line was shown to have a grossly normal karyotype and to restore higher levels of GATA6 protein as expected (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1J and K</xref>).</p><p>The impaired CM generation from <italic>GATA6</italic> mutant hESCs may be due to deficient CPC specification. Therefore, RT-qPCR assays were performed on <italic>GATA6</italic><sup>+/-</sup>, <italic>GATA6</italic><sup>-/-</sup> and WT cells harvested at day 6 of cardiac differentiation to examine the expression levels of the CPC markers <italic>NKX2.5</italic>, <italic>TBX5</italic>, <italic>TBX20</italic>, and <italic>GATA4</italic>. CPC marker expression levels were significantly reduced in <italic>GATA6</italic><sup>+/-</sup> and <italic>GATA6</italic><sup>-/-</sup> cells relative to WT controls, indicating a defect in CPC specification (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). At this time point there was a clear trend but not a statistically significant difference in the expression levels of CPC markers comparing the <italic>GATA6</italic><sup>+/-</sup> and <italic>GATA6</italic><sup>-/-</sup> genotypes. We also analyzed expression levels for markers of the first heart field (<italic>HAND1</italic> and <italic>SMARCD3</italic>) and the second heart field (SHF) (<italic>ISL1</italic>). All were significantly depleted in the GATA6<sup>-/-</sup> cells, while both <italic>ISL1</italic> and <italic>SMARCD3</italic> (but not <italic>HAND1</italic>) levels were significantly lower in the GATA6<sup>+/-</sup> cells. We note that an RT-qPCR time course showed that CPC marker expression level was increased (although not to WT levels) in <italic>GATA6</italic><sup>+/-</sup> cells at later stages (days 8–11) while <italic>GATA6</italic><sup>-/-</sup> CPC gene expression levels remained ‘flat’ in comparison with no increase over time (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>).</p><p><italic>GATA6</italic><sup>+/+</sup>, <italic>GATA6</italic><sup>+/-</sup>, and <italic>GATA6</italic><sup>-/-</sup> hESCs were differentiated toward the CM lineage using an alternative protocol based on chemical manipulation of the WNT pathway (<xref ref-type="bibr" rid="bib35">Lian et al., 2012</xref>; CHIR protocol, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B–E</xref>) to confirm if the phenotype is consistent as observed using the cytokine-based protocol. In vitro cardiac differentiation protocols for hPSCs are known to sometimes require extensive optimization due to cell line variation and can require testing various cell seeding densities, media component concentrations, and batch variations for crucial reagents (<xref ref-type="bibr" rid="bib32">Laco et al., 2018</xref>; <xref ref-type="bibr" rid="bib49">Pekkanen-Mattila et al., 2009</xref>). The CHIR protocol was overall suboptimal for cardiac differentiation using the H1-hESCs due to substantial variation in CM differentiation efficiency and the occasional failure to generate CMs in WT H1-hESCs. We therefore committed to using the cytokine-based protocol (<xref ref-type="fig" rid="fig1">Figure 1A</xref>) for the bulk of experiments in this study because it proved to be a more consistent CM differentiation protocol for the H1-hESCs. Nevertheless, in successful experiments performed using the CHIR protocol we observed the same phenotype in <italic>GATA6</italic><sup>-/-</sup> cells and <italic>GATA6</italic><sup>+/-</sup> cells using the CHIR protocol as with the cytokine-based protocol (data not shown), consistent with a previous report (<xref ref-type="bibr" rid="bib58">Sharma et al., 2020</xref>). Bulk RNA-seq was performed at day 5 using the CHIR protocol (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C–E</xref>). Principal component analysis (PCA) showed that the cells derived from each genotype were well separated from each other (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>). Differential gene expression and gene ontology (GO) analyses revealed that <italic>GATA6</italic><sup>-/-</sup> cells had strongly reduced expression levels of cardiac development-related gene sets including ‘OFT septum morphogenesis’ and ‘heart development’ compared to WT controls (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2D</xref>). Furthermore, while <italic>GATA6</italic><sup>+/-</sup> cells had relatively higher expression levels for many of these genes compared to <italic>GATA6</italic><sup>-/-</sup> cells, numerous CPC regulatory genes showed decreased levels compared to WT controls (including <italic>NKX2.5</italic>, <italic>TBX20</italic>, <italic>TBX5</italic>, <italic>MEF2C</italic>, and <italic>HAND2</italic>; <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2E</xref>), confirming an impairment of CPC development in differentiating <italic>GATA6</italic> mutant hESCs. GO analysis of genes with increased expression levels in <italic>GATA6</italic><sup>-/-</sup> cells relative to WT included gene sets such as ‘nervous system development’ (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2D</xref>), suggesting a bias toward a non-cardiac genetic signature. Notably, gene sets related to retinoic acid (RA) signaling were significantly increased in GATA6<sup>-/-</sup> cells relative to WT (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2D</xref>), and <italic>ALDH1A2</italic> expression (the main enzyme that generates RA) was increased in <italic>GATA6</italic><sup>-/-</sup> cells relative to WT from days 4–6 using the cytokine-based protocol (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2F</xref>), consistent with a previous study of cardiac differentiation using <italic>GATA6</italic> loss-of-function hiPSCs (<xref ref-type="bibr" rid="bib58">Sharma et al., 2020</xref>). Proper RA signaling is crucial for cardiogenesis including OFT development and cardiac chamber morphogenesis (<xref ref-type="bibr" rid="bib50">Perl and Waxman, 2019</xref>), and inhibiting excessive RA signaling in <italic>GATA6</italic> mutant hiPSCs was shown to partially rescue CPC marker expression (<xref ref-type="bibr" rid="bib58">Sharma et al., 2020</xref>). Thus, upregulated RA signaling in <italic>GATA6</italic><sup>-/-</sup> hESCs during the CPC developmental stage may partially underlie the CM differentiation defects.</p><p>Examining protein expression at multiple stages during cardiac differentiation revealed the earliest (and highest) expression level for GATA6 at day 2 of differentiation (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). The impaired CPC development in <italic>GATA6</italic><sup>+/-</sup> and <italic>GATA6</italic><sup>-/-</sup> cells may therefore be due to defective cardiac mesoderm patterning during the early stages of cardiogenesis. We examined co-expression of the precardiac mesoderm markers KDR and PDGFRα (KP) (<xref ref-type="bibr" rid="bib29">Kattman et al., 2011</xref>) using flow cytometry from days 3–5 of cardiac differentiation (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). At day 3, there was no significant difference in the %K<sup>+</sup>P<sup>+</sup> cells between genotypes (~45% K<sup>+</sup>P<sup>+</sup>), but by day 5 the %K<sup>+</sup>P<sup>+</sup> increased to ~72% in WT and <italic>GATA6</italic><sup>+/-</sup> cells, while the %K<sup>+</sup>P<sup>+</sup> was markedly reduced in <italic>GATA6</italic><sup>-/-</sup> cells (~22%, <xref ref-type="fig" rid="fig2">Figure 2B and C</xref>). This is consistent with previous reports where sorting and reseeding K<sup>+</sup>P<sup>+</sup> cells at day 3 of cardiac differentiation generated both mesenchymal cells and CMs but day 5 sorted K<sup>+</sup>P<sup>+</sup> cells gave rise predominantly to CMs, indicating that day 5 KP expression is relatively enriched for precardiac mesoderm (<xref ref-type="bibr" rid="bib29">Kattman et al., 2011</xref>; <xref ref-type="bibr" rid="bib68">Takeda et al., 2018</xref>). <italic>GATA6</italic><sup>+/-</sup> cells had a small but significant decrease in the %K<sup>+</sup>P<sup>+</sup> cells at day 4 relative to WT (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A and B</xref>), suggesting that the developing K<sup>+</sup>P<sup>+</sup> cardiac mesoderm in <italic>GATA6</italic><sup>+/-</sup> cells is temporarily defective or delayed relative to WT controls. Notably, the decreased %K<sup>+</sup>P<sup>+</sup> observed at day 4 (<italic>GATA6</italic><sup>+/-</sup> and <italic>GATA6</italic><sup>-/-</sup> cells) and day 5 (<italic>GATA6</italic><sup>-/-</sup> cells) relative to WT cells was due to reduced KDR but not PDGFRα expression (<xref ref-type="fig" rid="fig2">Figure 2D and E</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A and B</xref>), indicating that KDR is (directly or indirectly) regulated by GATA6 during cardiac mesoderm patterning.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>GATA6 is required for cardiac mesoderm development.</title><p>(<bold>A</bold>) Western blot time course using protein lysates from <italic>GATA6</italic><sup>+/+</sup> human embryonic stem cells (hESCs) probed for GATA6 with β-actin used as a loading control. (<bold>B</bold>) Flow cytometry quantification for % KDR and PDGFRα double-positive (%K<sup>+</sup>P<sup>+</sup>) cells from days 3–5 of cardiac differentiation of <italic>GATA6</italic><sup>+/+</sup>, <italic>GATA6</italic><sup>+/-</sup>, or <italic>GATA6</italic><sup>-/-</sup> hESCs (n ≥ 4). Asterisks indicate statistical significance comparing <italic>GATA6</italic><sup>-/-</sup> and WT on day 4 or 5 of cardiac differentiation. (<bold>C</bold>) Day 5 flow cytometry quantification for %K<sup>+</sup>P<sup>+</sup> cells (n = 7). (<bold>D</bold>) Representative flow cytometry plots for day 5 %K<sup>+</sup>P<sup>+</sup> cells. (<bold>E</bold>) Day 5 flow cytometry quantification (n = 7) for %KDR<sup>+</sup> (left) or PDGFRα<sup>+</sup> (right). (<bold>F</bold>) Representative flow cytometry plots for day 2 %BRACHYURY<sup>+</sup> cells (red) overlaid IgG stained controls (blue). (<bold>G</bold>) Quantification for day 2 or day 3 %BRACHYURY<sup>+</sup> cells (n = 4). (<bold>H</bold>) RT-qPCR for day 2 <italic>T</italic>, <italic>EOMES</italic>, <italic>MESP1</italic>, and <italic>MESP2</italic> expression levels normalized to <italic>GATA6</italic><sup>+/+</sup> samples (n = 6). Data represents the mean ± SEM, with significance indicated as **p&lt;0.01, ****p&lt;0.0001, and ns indicating not significant by two-way ANOVA (<bold>B, G</bold>) or one-way ANOVA (C, E, H) with Tukey’s multiple-comparison test. The labels w4, w2 (wildtype), m2, m5 (heterozygous), and m11, m14 (homozygous) refer to the isogenic wildtype and mutant hESC clones (see <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Western blots in panel A.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-100797-fig2-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Flow cytometry in panels B, C, E and G.</title><p>First tab includes KP flow cytometry in panels B, C and E. Second tab includes BRACHYURY flow cytometry in panel G.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-100797-fig2-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title>RT-qPCR in panel H.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-100797-fig2-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100797-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>KDR and PDGFRα cardiac mesoderm analysis at day 4.</title><p>(<bold>A</bold>) Representative flow cytometry plots at day 4 of cardiac differentiation analyzing the % KDR and PDGFRα double-positive cells (%K<sup>+</sup>P<sup>+</sup>) from <italic>GATA6</italic><sup>+/+</sup>, <italic>GATA6</italic><sup>+/-</sup>, or <italic>GATA6</italic><sup>-/-</sup> hESCs. (<bold>B</bold>) Quantification of day 4 flow cytometry data for %K<sup>+</sup>P<sup>+</sup> double-positive, %KDR<sup>+</sup> single positive, or %PDGFRα<sup>+</sup> single-positive cells (n = 6). Data represent the mean ± SEM, with statistical significance indicated as *p&lt;0.05 and ns indicating not significant by one-way repeated measures ANOVA with Holm–Šídák’s multiple-comparison test.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>KP flow cytometry in panel B.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-100797-fig2-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100797-fig2-figsupp1-v1.tif"/></fig></fig-group><p>We next sought to determine whether GATA6 loss-of-function impaired mesoderm induction by analyzing the expression of the pan-mesoderm marker BRACHYURY (<italic>T</italic>). Flow cytometry performed on WT, <italic>GATA6</italic><sup>+/-</sup>, or <italic>GATA6</italic><sup>-/-</sup> cells at day 2 or 3 of cardiac differentiation revealed no significant difference in abundance of BRACHYURY<sup>+</sup> cells between genotypes (<xref ref-type="fig" rid="fig2">Figure 2F and G</xref>). Likewise, there was no significant change in transcript levels for <italic>T</italic> or the mesendoderm marker <italic>EOMES</italic>, or mesoderm markers MESP1, or MESP2 at day 2 when assessed by RT-qPCR (<xref ref-type="fig" rid="fig2">Figure 2H</xref>). These results indicate that <italic>GATA6</italic> mutant hESCs have the capacity to differentiate into a nascent mesendoderm/early mesoderm population that is deficient in patterning cardiac mesoderm.</p></sec><sec id="s2-2"><title>Transcriptome analysis of <italic>GATA6</italic> mutant hESCs during early mesoderm patterning</title><p>During gastrulation, sequentially lineage-restrictive mesodermal cell populations emerge along a developmental trajectory involving primitive streak to lateral mesoderm formation, followed by cardiac mesoderm patterning (<xref ref-type="bibr" rid="bib40">Miquerol and Kelly, 2013</xref>). As <italic>GATA6</italic> loss-of-function hESCs differentiated to an emergent mesendoderm/mesoderm stage but failed to properly generate cardiac mesdoderm, we hypothesized that GATA6 is required during the earliest stages of lateral and precardiac mesoderm patterning. GATA6-regulated genes important during these early mesoderm patterning stages were investigated by performing bulk RNA-seq at day 2 or 3 of cardiac differentiation (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A and B</xref>). Again, PCA showed the profiles representing each genotype were well separated. GO analysis and gene set enrichment analysis (GSEA) using the biological process (BP) subcollection for differentially expressed genes (DEGs; defined as p-adj&lt;0.05 and log<sub>2</sub>(fold change)&gt;0.5) comparing <italic>GATA6</italic><sup>-/-</sup> to WT samples revealed decreased enrichment for GO terms including ‘heart development’ (e.g., <italic>HAND1</italic>) and ‘OFT septum morphogenesis’ (e.g., <italic>NRP1</italic>) at days 2 and 3, suggesting a disruption of early cardiac signature genes (<xref ref-type="fig" rid="fig3">Figure 3A, C and D</xref>). The decreased enrichment for the ‘OFT septum morphogenesis’ GO term is consistent with the conclusions of a previous study of <italic>GATA6</italic> mutations in hPSCs in the context of cardiac differentiation (<xref ref-type="bibr" rid="bib58">Sharma et al., 2020</xref>); however, the results presented here implicate this program at a much earlier developmental stage (D2 mesendoderm/lateral mesoderm). Conversely, GO analysis of increased DEGs in <italic>GATA6</italic><sup>-/-</sup> samples relative to WT at days 2 and 3 included ‘extracellular matrix (ECM) organization’, ‘skeletal system development’, and ‘AP axis specification’ (<xref ref-type="fig" rid="fig3">Figure 3B and D</xref>), suggesting that <italic>GATA6</italic><sup>-/-</sup> cells are biased to other lineages such as paraxial mesoderm or retain an early mesodermal phenotype by day 3.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Transcriptome analysis at early mesoderm patterning stages.</title><p>(<bold>A</bold>) Gene ontology (GO) analysis for biological process (BP) from decreased differentially expressed genes (dDEGs) identified comparing <italic>GATA6</italic><sup>-/-</sup> to WT samples from day 2 RNA-seq data (left). Heatmap for genes related to BMP signaling from day 2 RNA-seq shown on the right. Color gradient on heatmap indicates relative gene expression levels. (<bold>B</bold>) GO analysis (BP) of increased DEGs identified comparing <italic>GATA6</italic><sup>+/-</sup> to WT samples from day 2 RNA-seq (left). Heatmap for genes related to negative regulation of canonical WNT pathway from day 2 RNA-seq shown on the right. (<bold>C</bold>) Volcano plot for day 2 <italic>GATA6</italic><sup>-/-</sup> sample RNA-seq gene expression data relative to WT controls. Dots represent genes, red indicates p-adj&lt;0.05 and black indicates p-adj&gt;0.05. (<bold>D</bold>) Gene set enrichment analysis (GSEA) (BP) of <italic>GATA6</italic><sup>-/-</sup> cells relative to WT controls from day 3 RNA-seq data. NES indicates normalized enrichment score. (<bold>E</bold>) Heatmap for BMP signaling genes from day 3 RNA-seq data. (<bold>F</bold>) Western blots using protein lysates from <italic>GATA6</italic><sup>+/+</sup>, <italic>GATA6</italic><sup>+/-</sup> or <italic>GATA6</italic><sup>-/-</sup> cells at day 2 of cardiac differentiation probed with antibodies recognizing phospho-SMAD1/5/9, phospho-SMAD2/3, total SMAD2/3, non-phospho-β-catenin, and total β-catenin with β-actin used as a loading control. (<bold>G</bold>) GSEA analysis of day 2 or 3 RNA-seq gene expression data (<italic>GATA6</italic><sup>-/-</sup> relative to WT) using the day 2 lateral mesoderm (relative to human embryonic stem cell [hESC], left) and day 3 cardiac mesoderm (relative to day 2 lateral mesoderm, right) during hESC cardiac differentiation datasets from <xref ref-type="bibr" rid="bib31">Koh et al., 2016</xref>. FDR indicates false discovery rate. (<bold>H</bold>) Heatmaps from RNA-seq day 2 (left) or 3 (right) data using core enrichment genes identified in (<bold>G</bold>) for lateral mesoderm (relative to hESCs) and cardiac mesoderm (relative to lateral mesoderm). (<bold>I</bold>) Heatmap showing enriched paraxial mesoderm gene expression in the mutant cells.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Western blots in panel F.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-100797-fig3-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Original unmarked western blot images in panel F.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100797-fig3-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100797-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>RNA-seq analysis following cardiac differentiation at day 2 or 3.</title><p>(<bold>A</bold>) Number of differentially expressed genes (DEGs) identified when comparing <italic>GATA6</italic><sup>+/-</sup> and <italic>GATA6</italic><sup>-/-</sup> samples to <italic>GATA6</italic><sup>+/+</sup> controls from day 2 and 3 RNA-seq data. (<bold>B</bold>) Principal component analysis (PCA) for <italic>GATA6</italic><sup>+/+</sup>, <italic>GATA6</italic><sup>+/-</sup>, and <italic>GATA6</italic><sup>-/-</sup> profiles from day 2 or 3 RNA-seq. Data is representative of at least two independent biological replicates per sample. (<bold>C</bold>) Day 2 and 3 GO (BP) analysis using dDEGs identified comparing <italic>GATA6</italic><sup>+/-</sup> to WT samples. (<bold>D</bold>) Heatmaps for OFT septum morphogenesis and cardiac development related genes from day 3 RNA-seq. Color gradient indicates relative gene expression levels. (<bold>E</bold>) Venn diagram comparisons of dDEGs (relative to WT) identified by day 2 or 3 RNA-seq of <italic>GATA6</italic><sup>+/-</sup> and <italic>GATA6</italic><sup>-/-</sup> samples. (<bold>F</bold>) Volcano plots for day 2 or 3 <italic>GATA6</italic><sup>+/-</sup> sample RNA-seq gene expression data relative to WT. Dots represent genes, red indicates p-adj&lt;0.05, and black indicates p-adj&gt;0.05. (<bold>G</bold>) Heatmaps for WNT and BMP related genes from day 2 RNA-seq. (<bold>H</bold>) Gene set enrichment analysis (GSEA) analysis of day 2 RNA-seq gene expression data (<italic>GATA6</italic><sup>-/-</sup> relative to WT) using the GATA6, EOMES, and SMAD2/3 co-binding during hESC-DE differentiation dataset from <xref ref-type="bibr" rid="bib6">Chia et al., 2019</xref> and EOMES ME direct activation dataset from <xref ref-type="bibr" rid="bib73">Tosic et al., 2019</xref>. NES indicates normalized enrichment score; FDR indicates false discovery rate.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100797-fig3-figsupp1-v1.tif"/></fig></fig-group><p><italic>GATA6</italic><sup>+/-</sup> samples also had reduced expression levels for genes associated with cardiac GO terms such as ‘cardiac muscle contraction’ and ‘OFT septum morphogenesis’ when comparing to WT controls at day 3 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C and D</xref>). Indeed, there was overlap for many of the decreased DEGs (dDEGs) observed in <italic>GATA6</italic><sup>+/-</sup> and <italic>GATA6</italic><sup>-/-</sup> cells at day 2 or day 3 (relative to WT) including cardiac development genes such as <italic>ERBB4</italic> (important for endocardial cushion and ventricular trabeculae development <xref ref-type="bibr" rid="bib15">Gassmann et al., 1995</xref>), the SHF-related transcription factor <italic>HAND2</italic>, and the cardiac mesoderm marker <italic>LRRC32</italic> (<xref ref-type="bibr" rid="bib37">Loh et al., 2016</xref>), although the decrease in expression levels for these genes relative to WT was not as severe in the <italic>GATA6</italic><sup>+/-</sup> genotype as for <italic>GATA6</italic><sup>-/-</sup> (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D–F</xref>).</p><p>We observed dysregulation of genes related to the WNT and BMP networks in <italic>GATA6</italic><sup>-/-</sup> samples relative to WT at day 2 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1G</xref>) and GO and GSEA revealed decreased levels of ‘positive regulation of the BMP pathway’ and increased levels of ‘negative regulation of canonical WNT pathway’ at day 2 or 3 relative to WT (<xref ref-type="fig" rid="fig3">Figure 3A, B, D and E</xref>). Several dDEGs identified in <italic>GATA6</italic><sup>-/-</sup> cells at day 2 or 3 relative to WT samples included negative regulators of WNT signaling, including <italic>SFRP1</italic> and <italic>TLE1</italic> (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E and G</xref>), and antagonists of the BMP pathway, such as <italic>BMPER</italic> and <italic>SMAD6</italic> (<xref ref-type="fig" rid="fig3">Figure 3A and E</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E and G</xref>), indicating that the overall transcriptional response induced by the WNT and BMP pathways is dysregulated. <italic>GATA6</italic><sup>+/-</sup> cells also exhibited perturbed gene expression for several WNT- and BMP-related genes (at an intermediate level to those observed in <italic>GATA6</italic><sup>-/-</sup> cells) at day 2 or 3 relative to WT (<xref ref-type="fig" rid="fig3">Figure 3E</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1G</xref>). Mesoderm patterning is controlled by the input of WNT, BMP, and TGFβ signaling and dysfunction in these pathways cause severe developmental defects (<xref ref-type="bibr" rid="bib54">Prummel et al., 2020</xref>; <xref ref-type="bibr" rid="bib30">Kimelman and Griffin, 2000</xref>). Therefore, the cardiac defects caused by GATA6 loss-of-function may be caused by these alterations in WNT and BMP signaling.</p><p>We examined activity of the BMP, TGFβ, and WNT pathways by analyzing the effector proteins SMAD1/5/9 (BMP activated), SMAD2/3 (TGFβ activated), and β-catenin (WNT activated) by western blotting at day 2. There was no change in the levels of active phospho-SMAD1/5/9, phospho-SMAD2/3, or non-phospho-β-catenin when comparing <italic>GATA6</italic><sup>+/-</sup>, <italic>GATA6</italic><sup>-/-</sup>, and WT cells (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). These results indicate that GATA6 regulates the transcriptional response of genes activated by the BMP and WNT pathways downstream of canonical effector protein activation.</p><p>To further examine the impact of <italic>GATA6</italic> loss-of-function on early mesoderm patterning, we correlated RNA-seq data from a study examining hESC differentiation toward cardiac mesoderm (<xref ref-type="bibr" rid="bib31">Koh et al., 2016</xref>) to our day 2 or 3 RNA-seq data. GSEA using increased DEGs at day 2 (lateral mesoderm) or 3 (precardiac mesoderm) from <xref ref-type="bibr" rid="bib31">Koh et al., 2016</xref> revealed significantly reduced enrichment in our <italic>GATA6</italic><sup>-/-</sup> samples (relative to WT) on day 2 or 3, respectively (<xref ref-type="fig" rid="fig3">Figure 3G and H</xref>). Furthermore, <italic>GATA6</italic><sup>+/-</sup> cells had partially reduced expression for these lateral and precardiac mesoderm genes relative to WT cells (<xref ref-type="fig" rid="fig3">Figure 3H</xref>), suggesting that the impaired CPC and CM differentiation observed for <italic>GATA6</italic><sup>+/-</sup> hESCs originates as disrupted lateral and cardiac mesoderm patterning. We additionally compared the increased DEGs at day 2 from Koh et al. for paraxial mesoderm and our day 2 RNA-seq data and observed increased expression for these genes in <italic>GATA6</italic><sup>-/-</sup> cells relative to controls (<xref ref-type="fig" rid="fig3">Figure 3I</xref>), further supporting the notion that the <italic>GATA6</italic><sup>-/-</sup> hESCs are at biased toward a paraxial mesoderm-like genetic signature.</p><p>A previous study of GATA6 function during DE differentiation from hESCs reported an interaction between GATA6, EOMES, and SMAD2/3 to co-regulate genes important during mesendoderm and transition to DE development (<xref ref-type="bibr" rid="bib6">Chia et al., 2019</xref>). DE and cardiac mesoderm originate from a bipotent germlayer mesendoderm population (<xref ref-type="bibr" rid="bib66">Tada et al., 2005</xref>) and likely share a gene expression signature at this early stage. We therefore performed GSEA using the CHIP-seq dataset for triple-overlap of GATA6, EOMES, and SMAD2/3 during early DE differentiation from <xref ref-type="bibr" rid="bib6">Chia et al., 2019</xref> and found a significantly decreased enrichment in <italic>GATA6</italic><sup>-/-</sup> cells relative to WT at day 2 for putative direct GATA6 target genes (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1H</xref>). EOMES is an important transcriptional regulator of anterior mesoderm development (<xref ref-type="bibr" rid="bib53">Probst et al., 2021</xref>), and as GATA6 was shown to interact with EOMES during early DE differentiation (<xref ref-type="bibr" rid="bib6">Chia et al., 2019</xref>; <xref ref-type="bibr" rid="bib22">Heslop et al., 2022</xref>) we hypothesized that an interaction is similarly necessary during early lateral mesoderm patterning. We therefore performed GSEA using another published dataset of EOMES targets identified during mesoderm and DE (ME) differentiation in mouse ESCs (mESCs) (<xref ref-type="bibr" rid="bib73">Tosic et al., 2019</xref>). GSEA of our day 2 RNA-seq data with the ‘EOMES ME direct activation dataset’ human gene equivalents revealed a significant decrease in enrichment in <italic>GATA6</italic><sup>-/-</sup> cells relative to WT (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1H</xref>), supporting the notion that GATA6 cooperates with EOMES to co-regulate genes required for lateral mesoderm patterning.</p></sec><sec id="s2-3"><title>GATA6 binds to putative regulatory regions associated with BMP, WNT, and EOMES-related dDEGs</title><p>To determine the genomic localization of GATA6 occupancy during mesoderm patterning, we performed cleavage under targets and release using nuclease (CUT&amp;RUN) sequencing for GATA6 at day 2 of differentiation using GATA6<sup>+/+</sup> hESCs. 1273 significant differentially bound sites were identified for GATA6 relative to IgG control samples, associated with 953 transcriptional start sites (TSS) for unique genes (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Significant GATA6 binding sites predominately localized to intronic (46.03%) and distal intergenic (32.21%, &gt;5 kb from TSS) regions (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), consistent with previous reports of GATA6 binding distribution (<xref ref-type="bibr" rid="bib64">Sulahian et al., 2014</xref>; <xref ref-type="bibr" rid="bib13">Fisher et al., 2017</xref>). Transcription factor binding motif enrichment analysis revealed the strongest enrichment at GATA6 bound loci for ‘GATA’ motifs, as well as ‘LHX-like’ (LIM homeobox transcription factor; expressed in cardiac and other mesodermal derivatives; <xref ref-type="bibr" rid="bib7">Costello et al., 2015</xref>) and ‘EOMES’ motifs (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). GO analysis of the gene list nearby significant GATA6 binding peaks showed striking similarity to GO analysis from RNA-seq dDEGs in <italic>GATA6</italic><sup>-/-</sup> cells (relative to WT), including ‘OFT septum morphogenesis’, ‘BMP signaling pathway’, and ‘WNT signaling pathway’ (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Additionally, we observed an overlap of CUT&amp;RUN identified genes with day 2 (17.9%) and 3 (16.8%) RNA-seq dDEGs in <italic>GATA6</italic><sup>-/-</sup> cells (relative to WT) representing high likelihood direct targets of GATA6 including the cardiac development-related genes <italic>HAND1</italic> and <italic>MYOCD</italic> (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Visualizing the localization of these GATA6 peaks that mapped to day 2 and 3 dDEGs confirmed binding in intronic regions or at distal intergenic regions that overlapped with known enhancer-like signatures identified by the ENCODE Project (<xref ref-type="bibr" rid="bib44">Moore et al., 2020</xref>; <xref ref-type="fig" rid="fig4">Figure 4E</xref>). These included several WNT-related genes such as <italic>MCC</italic> and <italic>LGR5</italic>, as well as BMP-related genes including <italic>SMAD6</italic> (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). In <xref ref-type="fig" rid="fig4">Figure 4F</xref>, genes are highlighted in red that have GATA6 binding peaks in associated putative enhancers that are likely to be direct targets for the WNT/BMP networks. These are distinguished from WNT/BMP pathway genes that were not bound by GATA6 yet are downregulated in the GATA6 mutant cells and are more likely to be indirect targets.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>GATA6 CUT&amp;RUN analysis during early mesoderm patterning.</title><p>(<bold>A</bold>) Genomic distribution for significant GATA6 binding peaks identified by GATA6 CUT&amp;RUN at day 2 of cardiac differentiation (n = 3). (<bold>B</bold>) Transcription factor motif enrichment at GATA6 bound loci. (<bold>C</bold>) Gene ontology (GO) (biological process [BP]) analysis of the gene list associated with significant GATA6 binding peaks. (<bold>D</bold>) Venn diagram comparisons for day 2 GATA6 CUT&amp;RUN identified genes (green), day 2 decreased differentially expressed genes (dDEGs) (blue), and day 3 dDEGs (yellow) identified by RNA-seq (<italic>GATA6</italic><sup>-/-</sup> relative to WT). (<bold>E</bold>) Human genome browser representations of GATA6 CUT&amp;RUN data (blue tracks) aligned to select genes that are dDEGs identified by day 2 or 3 RNA-seq (<italic>GATA6</italic><sup>-/-</sup> relative to WT). Orange rectangles represent approximate location for distal enhancer-like signatures (dELS) via the ENCODE Project. Asterisks indicate significant GATA6 binding peaks (p&lt;0.003 relative to IgG controls). (<bold>F</bold>) Genes from the WNT and BMP signaling pathways that are significantly downregulated in the mutant cells compared to wildtype. Genes in red were found by CUT&amp;RUN to have GATA6 binding peaks in associated putative enhancers and are therefore likely to be direct targets. (<bold>G</bold>) Venn diagram comparisons for day 2 GATA6 CUT&amp;RUN identified genes (green), day 2 dDEGs (blue, <italic>GATA6</italic><sup>-/-</sup> relative to WT), and EOMES-CHIP-seq identified genes at day 2 of hESC-DE differentiation from <xref ref-type="bibr" rid="bib70">Teo et al., 2011</xref> (yellow). Inlayed heatmap indicates <italic>GATA6</italic><sup>+/+</sup>, <italic>GATA6</italic><sup>+/-</sup> and <italic>GATA6</italic><sup>-/-</sup> RNA-seq gene expression data at day 2 of cardiac differentiation for the 32 triple-overlap genes.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100797-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>GATA6 CUT&amp;RUN peaks overlap with previously published EOMES CHIP-seq peaks.</title><p>Human genome browser representations of GATA6 CUT&amp;RUN data at day 2 of cardiac differentiation (blue tracks) and EOMES CHIP-seq identified genes at day 2 of hESC-DE differentiation from <xref ref-type="bibr" rid="bib70">Teo et al., 2011</xref> (red tracks). Orange rectangles represent approximate location for distal enhancer-like signatures (dELS) via the ENCODE Project (indicated by black arrows). Asterisks indicate significant GATA6 binding peaks (p&lt;0.003 relative to IgG controls) and significant EOMES binding peaks as defined by <xref ref-type="bibr" rid="bib70">Teo et al., 2011</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100797-fig4-figsupp1-v1.tif"/></fig></fig-group><p>Day 2 GATA6 CUT&amp;RUN data revealed an enrichment for binding to sequences containing EOMES motifs (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). We compared our day 2 GATA6 CUT&amp;RUN and RNA-seq data to previously published EOMES CHIP-seq data performed on hESCs at day 2 of DE differentiation (<xref ref-type="bibr" rid="bib70">Teo et al., 2011</xref>). Comparing these datasets revealed 32 genes that had triple-overlap of day 2 GATA6 CUT&amp;RUN identified genes (953 genes nearby significantly bound sites), day 2 RNA-seq dDEGs, and EOMES CHIP-seq targets (<xref ref-type="bibr" rid="bib70">Teo et al., 2011</xref>; <xref ref-type="fig" rid="fig4">Figure 4G</xref>). Among this list of triple-overlap genes are known cardiac development factors including <italic>LGR5</italic>, which was reported to be required for hESC-CM differentiation (<xref ref-type="bibr" rid="bib28">Jha et al., 2017</xref>), and <italic>PRDM1</italic>, which is expressed in the SHF and involved in OFT morphogenesis (<xref ref-type="bibr" rid="bib79">Vincent et al., 2014</xref>). Visualizing the location of these triple-overlap genes confirmed that the GATA6 peaks directly overlapped with many EOMES CHIP-seq peaks (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>), suggesting that GATA6 and EOMES interact to co-regulate genes required for precardiac mesoderm patterning.</p></sec><sec id="s2-4"><title>GATA6 interactome analysis during precardiac to cardiac mesoderm patterning stages</title><p>We next analyzed the GATA6 interactome using rapid immunoprecipitation of endogenous proteins (RIME) on WT cells at day 2 or 4 of cardiac differentiation to define the chromatin associated protein interactions. 99 significant interacting proteins at day 2 and 52 unique proteins at day 4 of cardiac differentiation were identified bound to GATA6 compared to IgG control samples (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). EOMES was one of the most enriched proteins bound to GATA6 at day 2 but was not identified in the day 4 GATA6-RIME analysis (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). 81.8% of proteins identified by GATA6-RIME at day 2 were not encoded by significantly DEGs identified by day 2 RNA-seq (<italic>GATA6</italic><sup>-/-</sup> vs. WT) while 18.2% were, including TLE1, VRTN, and ZIC2 (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>), indicating that GATA6 functions in parallel with most interacting proteins identified. Many of the significantly bound proteins were components of chromatin remodeling complexes such as members of the SWI/SNF complex (e.g., SMARCC1, SMARCA4, and ARID1A), which functions to mobilize nucleosomes and promote DNA accessibility (<xref ref-type="bibr" rid="bib41">Mittal and Roberts, 2020</xref>), and the Nucleosome Remodeling and Deacetylase (NuRD) complex (e.g., KDM1A, MTA1/2/3, and GATAD2A), a chromatin remodeling complex associated with transcriptional repression (<xref ref-type="bibr" rid="bib39">Millard et al., 2016</xref>; <xref ref-type="fig" rid="fig5">Figure 5B</xref>). GATA6 protein interactions were also observed for other epigenetic and transcriptional regulators including those related to histone deacetylation (i.e., HDAC2) and mRNA splicing (i.e., SF1, <xref ref-type="fig" rid="fig5">Figure 5B and D</xref>). Interestingly, WNT/β-catenin transcriptional regulators were identified bound to GATA6, particularly at day 2 of cardiac differentiation, including the β-catenin transcriptional co-activator EP300 (<xref ref-type="bibr" rid="bib65">Sun et al., 2000</xref>), and the TCF/LEF transcriptional co-repressors CTBP1/2 (<xref ref-type="bibr" rid="bib77">Valenta et al., 2003</xref>; <xref ref-type="bibr" rid="bib8">Cuilliere-Dartigues et al., 2006</xref>) and TLE1 (<xref ref-type="bibr" rid="bib3">Brantjes et al., 2001</xref>; <xref ref-type="fig" rid="fig5">Figure 5B</xref>), suggesting that GATA6 may directly modulate the transcriptional response induced by WNT signaling by binding to these proteins.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>GATA6 interactome analysis during precardiac to cardiac mesoderm patterning stages.</title><p>(<bold>A</bold>) Venn diagrams showing unique proteins identified by RIME analysis performed on <italic>GATA6</italic><sup>+/+</sup> hESCs at day 2 or 4 of cardiac differentiation. Numbers in white text indicate enriched proteins identified by GATA6-RIME. G6 indicates GATA6, R indicates replicate (n = 2). (<bold>B</bold>) Enriched proteins identified by GATA6 RIME (spectral count &gt;5, unique peptides &gt;1). (<bold>C</bold>) Venn diagram comparing day 2 (blue) and 4 (yellow) GATA6-RIME-enriched proteins. (<bold>D</bold>) Gene ontology (GO) (biological process [BP]) analysis for GATA6-RIME-enriched proteins on day 2 or 4. (<bold>E</bold>) Western blots for GATA6, EOMES, and SMARCC1 performed on GATA6-immunoprecipitated (G6-IP) whole-cell protein lysates from <italic>GATA6</italic><sup>+/+</sup> and <italic>GATA6</italic><sup>-/-</sup> cells isolated at day 2 of cardiac differentiation. Input indicates whole-cell protein lysate controls.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Western blots (GATA6-IP) in panel E.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-100797-fig5-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Original unmarked western blot images in panel E.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100797-fig5-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100797-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Extended GATA6-RIME analysis.</title><p>(<bold>A</bold>) Graph depicts GATA6-RIME-enriched proteins (spectral count) identified at day 2 of cardiac differentiation and their corresponding day 2 RNA-seq gene expression level significance (p-adj, <italic>GATA6</italic><sup>-/-</sup> relative to WT). Dots indicate genes, black indicates p-adj&gt;0.05, red indicates decreased expression level (p-adj&lt;0.05), green indicates increased expression level (p-adj&lt;0.5). (<bold>B</bold>) Venn diagram comparisons for GATA6-RIME-enriched proteins from day 2 (D2 G6) and 4 (D4 G6) of cardiac differentiation from the present study with day 4 GATA6-RIME (DE: D4 G6) or day 2 EOMES-RIME (DE: D2 EOMES) enriched proteins reported during hESC-DE differentiation from <xref ref-type="bibr" rid="bib21">Heslop et al., 2021</xref>; <xref ref-type="bibr" rid="bib22">Heslop et al., 2022</xref>. (<bold>C</bold>) Proteins identified in the Venn diagram comparisons of RIME data described in (<bold>B</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100797-fig5-figsupp1-v1.tif"/></fig></fig-group><p>Proteins identified by GATA6-RIME only at day 2 included the transcription factors EOMES and MIXL1 (both transcription factors involved in primitive streak formation and mesoderm patterning <xref ref-type="bibr" rid="bib37">Loh et al., 2016</xref>; <xref ref-type="bibr" rid="bib62">Stavish et al., 2020</xref>) as well at TLE1, EP300, and SMARCA5, while the unique day 4 proteins were all RNA binding proteins such as TAF15 (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). The overlapping day 2 and 4 GATA6-RIME results included many chromatin remodelers such as SMARCC1, SMARCA4, and KDM1A (<xref ref-type="fig" rid="fig5">Figure 5C</xref>), although the enrichment for these proteins was greater at day 2 compared to day 4 (<xref ref-type="fig" rid="fig5">Figure 5B</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). As day 2 of differentiation had the highest level of GATA6 expression and enrichment for RIME identified proteins, we performed GATA6 immunoprecipitation (IP) on <italic>GATA6</italic><sup>+/+</sup> and <italic>GATA6</italic><sup>-/-</sup> samples at day 2 and confirmed a weak interaction with EOMES and SMARCC1 in the WT samples, with no observable bands in <italic>GATA6</italic><sup>-/-</sup> samples (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). The EOMES and SMARCC1 protein bands identified in GATA6-IP samples were notably less than observed for the input controls; therefore, it is possible that the interaction between GATA6 and these proteins is indirect (i.e., GATA6 may be co-bound in a complex with EOMES and/or SMARCC1 among other proteins).</p><p>Previous studies performed GATA6-RIME at day 4 and EOMES-RIME at day 2 of DE differentiation (<xref ref-type="bibr" rid="bib21">Heslop et al., 2021</xref>; <xref ref-type="bibr" rid="bib22">Heslop et al., 2022</xref>), so we compared our day 2 and 4 GATA6-RIME data to these previously published RIME datasets (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). 26 proteins were present in all four datasets (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B and C</xref>), implying there is a common interaction between GATA6 and various remodeler proteins, the transcription factor SALL4, and the TCF/LEF co-repressors CTBP1/2 during mesendoderm patterning toward both cardiac mesoderm and DE lineages. Protein interactions unique to day 2 GATA6- and EOMES-RIME included MIXL1, SMARCC2, and ARID1B and may represent protein interactions specific to mesendoderm development (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>). Notably, EOMES and the WNT-related proteins TLE1 and EP300 were not identified in our day 4 dataset but were present in our day 2 GATA6-RIME data and the published EOMES and GATA6-RIME datasets during early DE development (<xref ref-type="bibr" rid="bib21">Heslop et al., 2021</xref>; <xref ref-type="bibr" rid="bib22">Heslop et al., 2022</xref>). Therefore, an interaction between GATA6 and these proteins appears to be relinquished by the cardiac mesoderm stage (day 4) but persists during DE patterning. Cardiac differentiation requires a transient inhibition of the canonical WNT signaling pathway (<xref ref-type="bibr" rid="bib76">Ueno et al., 2007</xref>), and as day 4 of our cardiac differentiation protocol occurs after WNT inhibition these varying protein interactions may reflect the differing contributions of the WNT pathway during cardiac and DE differentiation.</p></sec><sec id="s2-5"><title>Early manipulation of the WNT and BMP pathways partially rescues the CM defects in GATA6 mutant hESCs</title><p><italic>LGR5</italic>, a component of the WNT pathway (<xref ref-type="bibr" rid="bib9">de Lau et al., 2014</xref>), was among the most significant dDEGs identified from day 2 or 3 RNA-seq in GATA6<sup>-/-</sup> cells (relative to WT) and was also found significantly bound by GATA6 (and in a previous study, EOMES; <xref ref-type="bibr" rid="bib70">Teo et al., 2011</xref>) in WT cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). As LGR5 is required for efficient CM differentiation in hPSCs (<xref ref-type="bibr" rid="bib28">Jha et al., 2017</xref>; <xref ref-type="bibr" rid="bib56">Sahara et al., 2019</xref>), we hypothesized that infection with a doxycycline (DOX)-inducible <italic>LGR5</italic>-expressing lentivirus might rescue the cardiac defects in <italic>GATA6</italic><sup>-/-</sup> hESCs. In <italic>GATA6</italic><sup>-/-</sup> hESCs that had been transduced with the inducible-<italic>LGR5</italic> lentivirus (i<italic>LGR5</italic>), DOX was added from days 1–4 of cardiac differentiation using the cytokine-based protocol (<xref ref-type="fig" rid="fig6">Figure 6A</xref>) to mimic the <italic>LGR5</italic> expression pattern (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>); we validated that this increased <italic>LGR5</italic> expression in a DOX-dose-dependent manner (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). In all differentiation experiments using i<italic>LGR5</italic> treated with DOX (250 ng/mL), we did not observe generation of beating CMs. However, DOX treatment of i<italic>LGR5</italic>-transduced <italic>GATA6</italic><sup>-/-</sup> hESCs did yield a small but significant increase in the %K<sup>+</sup>P<sup>+</sup> population at day 5 of differentiation relative to empty vector (EV) transduced controls, associated with increased KDR expression (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Thus, <italic>LGR5</italic> expression can partially rescue a proportion of day 5 cardiac mesoderm in <italic>GATA6</italic><sup>-/-</sup> hESCs but cannot sufficiently improve subsequent CM differentiation.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Early manipulation of the WNT and BMP pathways partially rescues the cardiomyocyte (CM) defects in GATA6 loss-of-function human embryonic stem cells (hESCs).</title><p>(<bold>A</bold>) Schematic for treatment with DOX (days 1–4), CHIR (3 μM, days 0–2), and/or reduced BMP4 (5 ng/mL, days 0–2, indicated as ‘LB’) during CM directed differentiation using the cytokine-based protocol. (<bold>B</bold>) Day 5 flow cytometry quantification for %K<sup>+</sup>P<sup>+</sup> double-positive cells, %KDR<sup>+</sup> single-positive cells, or %PDGFRα<sup>+</sup> single-positive cells in WT or <italic>GATA6</italic><sup>-/-</sup> hESCs transduced with i<italic>LGR5</italic> or empty vector (EV) (n = 5). Significance indicated by *p&lt;0.05 according to one-way ANOVA and Tukey’s post hoc analysis. (<bold>C</bold>) %cTnT<sup>+</sup> CMs from days 13–18 of cardiac differentiation quantified by flow cytometry in WT or <italic>GATA6</italic><sup>-/-</sup> cells treated with CHIR LB or vehicle (DMSO) with normal BMP4 concentration treated control (n ≥ 6). (<bold>D</bold>) Flow cytometry at day 5 of cardiac differentiation to quantify %K<sup>+</sup>P<sup>+</sup> double-positive, %KDR<sup>+</sup> single-positive, or %PDGFRα<sup>+</sup> single-positive cells comparing WT or <italic>GATA6</italic><sup>-/-</sup> hESCs treated with CHIR LB with <italic>GATA6</italic><sup>+/+</sup> and <italic>GATA6</italic><sup>-/-</sup> hESCs controls treated with vehicle and normal BMP4 concentration (n ≥ 8). (<bold>E</bold>) %cTnT<sup>+</sup> CMs from days 13–18 of cardiac differentiation quantified by flow cytometry in <italic>GATA6</italic><sup>+/-</sup> or WT hESCs treated with CHIR (3 μM) or DMSO (n ≥ 7). Data represents the mean ± SEM, significance indicated by **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001 by two-tailed Student’s <italic>t</italic>-test (<bold>C</bold>) and two-way ANOVA (<bold>D, E</bold>) with Tukey’s multiple-comparison test.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Flow cytometry in panels B-E.</title><p>First tab includes KP flow cytometry in panels B and D. Second tab includes cTnT flow cytometry in panels C and E.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-100797-fig6-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100797-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Extended data for i<italic>LGR5</italic> and early CHIR treatment.</title><p>(<bold>A</bold>) RT-qPCR time course for relative <italic>LGR5</italic> expression in differentiating <italic>GATA6</italic><sup>+/+</sup>, <italic>GATA6</italic><sup>+/-</sup>, and <italic>GATA6</italic><sup>-/-</sup> human embryonic stem cells (hESCs) normalized to day 2 WT gene expression level (on left). Day 2 RT-qPCR quantification for relative <italic>LGR5</italic> expression level normalized to WT (on right, n = 6). (<bold>B</bold>) Day 4 RT-qPCR for relative <italic>LGR5</italic> expression level (normalized to WT) in i<italic>LGR5</italic> or EV transduced <italic>GATA6</italic><sup>-/-</sup> hESCs treated with or without varying concentrations of DOX (30, 125, and 250 indicate ng/mL concentrations of DOX). (<bold>C</bold>) %cTnT<sup>+</sup> CMs from days 13–17 of cardiac differentiation quantified by flow cytometry in <italic>GATA6</italic><sup>-/-</sup> cells treated with CHIR (3 μM) or vehicle (n≥8). (<bold>D</bold>) Flow cytometry quantification for %K<sup>+</sup>P<sup>+</sup> double-positive cells at day 5 of cardiac differentiation from <italic>GATA6</italic><sup>-/-</sup> hESCs treated with CHIR and vehicle-treated <italic>GATA6</italic><sup>+/+</sup> or <italic>GATA6</italic><sup>-/-</sup> hESCs controls (n ≥ 3). Data represents the mean ± SEM, significance indicated by *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, by two-tailed Student’s <italic>t</italic>-test (<bold>C</bold>) or one-way ANOVA with Tukey’s multiple-comparisons test (<bold>A, D</bold>).</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>RT-qPCR in panels A and B.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-100797-fig6-figsupp1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6s1sdata2"><label>Figure 6—figure supplement 1—source data 2.</label><caption><title>cTnT and KP flow cytometry in panels C and D.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-100797-fig6-figsupp1-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100797-fig6-figsupp1-v1.tif"/></fig></fig-group><p>As LGR5 is a single component of the complex WNT pathway, we tested a broader pharmacological approach by using the WNT agonist CHIR to determine if early WNT activation could more efficiently rescue the cardiac defects in <italic>GATA6</italic><sup>-/-</sup> hESCs. We found that inclusion of CHIR (3 μM) from days 0–2 in differentiating <italic>GATA6</italic><sup>-/-</sup> hESCs yielded by day 13 small clusters of beating CMs (<xref ref-type="video" rid="video1">Video 1</xref>). When assessing quantitatively by flow cytometry the %cTnT<sup>+</sup> CMs in CHIR-treated <italic>GATA6</italic><sup>-/-</sup> cells relative to vehicle-treated controls, there was a variable trend for CM induction that was however not statistically significant (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>). Similarly, while the %K<sup>+</sup>P<sup>+</sup> cardiac mesoderm cells at day 5 was slightly increased upon CHIR treatment in <italic>GATA6</italic><sup>-/-</sup> cells, this was not a statistically significant improvement (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D</xref>).</p><media mimetype="video" mime-subtype="mp4" xlink:href="elife-100797-video1.mp4" id="video1"><label>Video 1.</label><caption><title>Inclusion of CHIR (3 μM) from days 0–2 in differentiating <italic>GATA6</italic><sup>-/-</sup> human embryonic stem cells (hESCs) yielded by day 13 small clusters of beating cardiomyocytes (CMs).</title><p>Shown is a representative cluster at day 16, ×10 magnification.</p></caption></media><p>BMP-related gene expression was also dysregulated at day 2 in <italic>GATA6</italic><sup>-/-</sup> cells and thus manipulation of the BMP4 concentration in combination with CHIR treatment from days 0–2 was tested to further promote CM rescue. Interestingly, we found that decreasing the BMP4 concentration (5 ng/mL) combined with CHIR treatment yielded small clusters of beating CMs (<xref ref-type="video" rid="video2">Video 2</xref>) more consistently than increasing the BMP4 concentration (data not shown) or treatment with CHIR on its own. Quantification by flow cytometry for %cTnT<sup>+</sup> CMs in <italic>GATA6</italic><sup>-/-</sup> cells treated with CHIR and the lower BMP4 concentration (CHIR LB) showed a small but significant increase (~4% cTnT<sup>+</sup>) relative to <italic>GATA6</italic><sup>-/-</sup> controls indicating that CM differentiation is partially rescued upon CHIR LB treatment (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Note that this treatment actually decreases efficiency for differentiation in the control WT cells. The %K<sup>+</sup>P<sup>+</sup> and %K<sup>+</sup> day 5 cardiac mesoderm population was also significantly increased with CHIR LB treatment in <italic>GATA6</italic><sup>-/-</sup> cells relative to untreated controls and was not significantly different than WT controls indicating a rescue of day 5 K<sup>+</sup>P<sup>+</sup> cardiac mesoderm (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). Taken together, these results indicate that modulating the early input of the WNT and BMP pathways in <italic>GATA6</italic><sup>-/-</sup> cells can rescue the cardiac mesoderm patterning defects and partially rescue subsequent CM differentiation.</p><media mimetype="video" mime-subtype="mp4" xlink:href="elife-100797-video2.mp4" id="video2"><label>Video 2.</label><caption><title>Decreasing the BMP4 concentration (5 ng/mL) combined with CHIR treatment yielded small clusters of beating cardiomyocytes (CMs) from GATA6-/- cells more consistently than increasing the BMP4 concentration or treatment with CHIR on its own.</title><p>Shown is a representative cluster at day 18, ×40 magnification.</p></caption></media><p><italic>GATA6</italic><sup>+/-</sup> cells also exhibited partial dysregulated gene expression related to WNT signaling via day 2 RNA-seq relative to WT controls (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1G</xref>). We therefore hypothesized that the addition of CHIR from days 0–2 in differentiating <italic>GATA6</italic><sup>+/-</sup> hESCs could rescue CM differentiation more potently than observed in <italic>GATA6</italic><sup>-/-</sup> hESCs. Indeed, we found that the %cTnT<sup>+</sup> CMs was significantly increased in <italic>GATA6</italic><sup>+/-</sup> cells supplemented with CHIR relative to vehicle-treated controls and was not significantly different from WT untreated controls, indicating an efficient rescue of CM differentiation (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). CHIR addition to WT hESCs had a deleterious effect on CM differentiation efficiency, with the %cTnT<sup>+</sup> CMs reduced from ~60% (DMSO treated) to ~25% (CHIR treated, <xref ref-type="fig" rid="fig6">Figure 6E</xref>), suggesting that there is a threshold ‘window’ for the degree of WNT pathway activation required during early primitive streak to mesoderm patterning stages and that reducing or exceeding this threshold has an adverse effect on later CM differentiation capacity. Furthermore, this data indicates that the rescue in CM differentiation efficiency in <italic>GATA6</italic><sup>+/-</sup> cells treated with CHIR was not due to an overall improvement in the general cardiac differentiation protocol, but rather related to correcting the consequence of loss of one <italic>GATA6</italic> allele.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We found that <italic>GATA6</italic> loss-of-function mutations severely disrupt CPC gene expression and impair CM differentiation, consistent with the results described by <xref ref-type="bibr" rid="bib58">Sharma et al., 2020</xref>. Here, we discovered that GATA6 is required very early in this process and that the later cardiac phenotypes observed in <italic>GATA6</italic><sup>+/-</sup> and <italic>GATA6</italic><sup>-/-</sup> hESCs originate from an early mesoderm patterning defect in which lateral and cardiac mesoderm genes fail to be expressed at normal levels. Gene networks induced by the WNT and BMP pathways that are normally required for primitive streak organization and subsequent anterior lateral mesoderm emergence are also mis-expressed when GATA6 is deficient. GATA6 CUT&amp;RUN analysis revealed binding at distal enhancer-like signatures nearby dDEGs identified by RNA-seq, and GATA6 binding was found to have a considerable overlap with previously published EOMES CHIP-seq data during early DE differentiation (<xref ref-type="bibr" rid="bib70">Teo et al., 2011</xref>) nearby many of these genes. Day 2 GATA6 RIME analysis confirmed binding with EOMES and various chromatin remodelers including components of the SWI/SNF and NuRD remodeling complexes that are known to regulate chromatin accessibility of cardiac lineage-specific gene networks (<xref ref-type="bibr" rid="bib34">Lei et al., 2012</xref>; <xref ref-type="bibr" rid="bib24">Hota et al., 2019</xref>; <xref ref-type="bibr" rid="bib25">Hota et al., 2022</xref>; <xref ref-type="bibr" rid="bib20">Herchenröther et al., 2023</xref>; <xref ref-type="bibr" rid="bib61">Shi et al., 2024</xref>). Furthermore, we found that early manipulation of the WNT pathway through CHIR treatment from days 0–2 rescued CM defects observed in <italic>GATA6</italic><sup>+/-</sup> hESCs while CHIR treatment and reduced BMP4 dosage rescued K<sup>+</sup>P<sup>+</sup> cardiac mesoderm and partially rescued CM differentiation in <italic>GATA6</italic><sup>-/-</sup> hESCs. Together, these results present multiple novel functions for GATA6 in regulating early precardiac mesoderm patterning during human cardiac differentiation.</p><p>WNT and BMP-related genes were dysregulated in <italic>GATA6</italic><sup>+/-</sup> and <italic>GATA6</italic><sup>-/-</sup> cells at day 2 and 3 of cardiac differentiation but β-catenin and SMAD protein activation was intact indicating that the transcriptional response of these pathways is defective rather than the upstream activation induced by morphogens. GATA6 RIME analysis revealed an interaction with several WNT transcriptional regulators including the β-catenin co-activator EP300 and the TCF/LEF transcriptional co-repressors TLE1 and CTBP1/2, and binding to these proteins could have positive or negative effects on their function. One potential mechanism is that GATA6 binds to these WNT regulators and prevents their repressive (or in the case for EP300, potentiating) function on TCF-mediated transcription, causing a net increase in the β-catenin transcriptional response. Indeed, there was an enrichment for negative regulation of the WNT signaling pathway at day 2 in <italic>GATA6</italic><sup>-/-</sup> cells according to RNA-seq data, suggesting that GATA6 loss-of-function increases feedback inhibition of TCF/LEF-mediated transcription. GATA6 CUT&amp;RUN analysis also revealed binding near many genes related to WNT and BMP signaling implying direct participation in modulating appropriate β-catenin/SMAD transcriptional responses. However, many WNT/BMP response genes dysregulated in <italic>GATA6</italic><sup>+/-</sup> and <italic>GATA6</italic><sup>-/-</sup> cells were not identified as targets by GATA6 CUT&amp;RUN, suggesting that another method for regulation is indirect, perhaps related to the interaction with chromatin remodelers affecting DNA accessibility.</p><p>RIME analysis revealed GATA6 bound to many chromatin remodelers including components of the SWI/SNF (e.g., SMARCA4) and NuRD (e.g., KDM1A) complexes at days 2 and 4 of cardiac differentiation. GATA6 is a pioneer transcription factor with specialized function to bind and promote accessibility of chromatin during CPC development (<xref ref-type="bibr" rid="bib58">Sharma et al., 2020</xref>), and GATA6, GATA4, and GATA3 have previously been shown to interact with various members of SWI/SNF complexes such as SMARCA4 (<xref ref-type="bibr" rid="bib58">Sharma et al., 2020</xref>; <xref ref-type="bibr" rid="bib21">Heslop et al., 2021</xref>; <xref ref-type="bibr" rid="bib67">Takaku et al., 2016</xref>; <xref ref-type="bibr" rid="bib36">Lickert et al., 2004</xref>). However, the molecular mechanism for how GATA6 modifies the accessibility of chromatin and mobilizes nucleosomes is unclear. The AP-1 pioneer factor interacts with SWI/SNF complexes to promote their localization to non-permissive regions of chromatin (<xref ref-type="bibr" rid="bib81">Wolf et al., 2023</xref>). GATA6 may function similarly, for example, by binding to SWI/SNF complex proteins and recruiting them to regions of closed chromatin containing lineage-specific enhancers where they then function to promote genomic accessibility. It is somewhat surprising that among all the SWI/SNF factors, the one that is known to be cardiac-specific (SMARCD3) was not found in the GATA6-RIME-enriched proteins. We note that SMARCD3 is expressed in the RNA-seq data as early as day 2. Although speculative, it may be that GATA6 primarily interacts with other SWI/SNF complexes prior to a subsequent role for SMARCD3 in cardiac specification.</p><p>The function of GATA6 during early mesoderm patterning presented in this study has unique implications toward understanding the pathogenesis of CHD and extra-cardiac phenotypes associated with human <italic>GATA6</italic> mutations. <italic>GATA6</italic> homozygous loss-of-function mutations have not been described in humans, most likely due to early embryonic lethality causing non-viable embryogenesis. This is consistent with the early mesoderm patterning defects of <italic>GATA6</italic><sup>-/-</sup> hESCs described in this study, previous reports of DE defects in <italic>GATA6</italic>-null hPSC lines (<xref ref-type="bibr" rid="bib60">Shi et al., 2017</xref>; <xref ref-type="bibr" rid="bib21">Heslop et al., 2021</xref>; <xref ref-type="bibr" rid="bib6">Chia et al., 2019</xref>; <xref ref-type="bibr" rid="bib72">Tiyaboonchai et al., 2017</xref>), as well as the early lethality reported in <italic>GATA6</italic> KO mice (<xref ref-type="bibr" rid="bib45">Morrisey et al., 1998</xref>). In the case of haploinsufficiency, CHD presenting as OFT or septal defects associated with heterozygous <italic>GATA6</italic> mutations may be due to defects that occur during early mesoderm patterning that diminish the later developmental pool of CPCs and CMs. Quite remarkably, profiles of cells at day 2 of differentiation already identify OFT morphogenesis as gene sets disturbed by loss of GATA6. Relatively minor changes in early mesoderm cell population numbers have recently been reported to associate with later heart defects in a mouse model of Cornelia de Lange syndrome using <italic>NPBL1</italic><sup>+/-</sup> mice (<xref ref-type="bibr" rid="bib5">Chea et al., 2024</xref>), and thus <italic>GATA6</italic> heterozygous mutations may similarly have a subtle negative effect on developing mesodermal cell populations to cause CHD. Human mutations in <italic>GATA6</italic> commonly associate with OFT defects, a primarily SHF-derived structure, and recent work has established that SHF lineage progenitors are derived from early defined mesodermal subpopulations (<xref ref-type="bibr" rid="bib84">Yang et al., 2022</xref>). Therefore, <italic>GATA6</italic> mutations might impair specific heart field progenitor populations based on the timing and positioning of these developing mesodermal populations in the primitive streak, long before the progenitors are associated with SHF. <italic>GATA6</italic> haploinsufficiency in humans also associates with endoderm defects such as pancreatic agenesis, and DE and early mesoderm co-develop from a common mesendoderm population adjacent to one another in the anterior primitive streak during gastrulation (<xref ref-type="bibr" rid="bib47">Murry and Keller, 2008</xref>). Defects in the regulatory functions of GATA6 during mesendoderm patterning, such as interactions with EOMES and specific chromatin remodelers, may cause downstream organ defects in both mesoderm and endoderm-derived organ systems in some patients with <italic>GATA6</italic> mutations. The data presented here focuses on early stages of mesoderm patterning and cardiac progenitor differentiation in the context of <italic>GATA6</italic> loss-of-function rather than CM profiling and is thus a limitation of our study. Future investigation of how heterozygous <italic>GATA6</italic> mutations impact CMs physiology such as cardiac chamber identity and CM function would be a worthwhile pursuit to expand our knowledge of how <italic>GATA6</italic> regulates CM differentiation in relation to human CHD.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>hPSC culture</title><p>hPSC lines were cultured on Matrigel (Corning BD354277)-coated tissue culture plates using StemFlex (Thermo Fisher Scientific A3349401) or mTESR Plus (Stem Cell Technologies 1000276) medium at 37°C and 5% CO<sub>2</sub>. Cells were passaged using Accutase Cell Detachment Solution (VWR 10761-312) and supplemented with 10 μM ROCK inhibitor (RI) Y-27632 (Selleckchem S1049) for 1 day. hPSCs were routinely tested for mycoplasma contamination using the LookOut Mycoplasma PCR Detection Kit (Sigma-Aldrich MP0035).</p></sec><sec id="s4-2"><title>iPSC generation</title><p>A skin biopsy was obtained from a patient with an atrial septal defect and congenital diaphragmatic hernia associated with a heterozygous frameshift mutation in <italic>GATA6</italic> (c.1071delG) (<xref ref-type="bibr" rid="bib85">Yu et al., 2014</xref>). Human dermal fibroblasts (HDFs) derived from this biopsy were transduced with four Sendai viruses expressing OCT3/4, SOX2, KLF4, and c-MYC using the CytoTune-iPS 2.0 Sendai Reprogramming Kit (Invitrogen A16517). Transduced HDFs were reprogrammed on CF1 mouse embryonic fibroblasts (MEFs) (Thermo Fisher Scientific A34180) with iPSC medium consisting of DMEM/F12 (VWR 16777-255) supplemented with 20% KnockOut serum replacement (KOSR, Thermo Fisher Scientific 10828010), 1% non-essential amino acids (Thermo Fisher Scientific), 1% <sc>l</sc>-glutamine (Corning 25-005Cl), 1% Penicillin:Streptomycin Solution (Corning 30-002CI), 0.0007% 2-mercaptoethanol (Thermo Fisher Scientific 21985023), 10 ng/mL bFGF (R&amp;D Systems 233-FB-025). Once iPSC colonies emerged, colonies were manually isolated and expanded into feeder-free conditions by culturing with mTESR1 (Stem Cell Technologies 85850) on Matrigel coated plates.</p></sec><sec id="s4-3"><title>CRISPR gene editing</title><p>The GATA6 mutant H1 (WA01, NIH #0043) hESC cell lines were established in a previous study (<xref ref-type="bibr" rid="bib60">Shi et al., 2017</xref>) using the H1-iCas9 cell line and CRISPR gene editing (<xref ref-type="bibr" rid="bib19">González et al., 2014</xref>) targeting the C-terminal ZnF domain (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A and B</xref>). The <italic>GATA6</italic> c.1071delG iPSC mutant allele was corrected to WT sequence to create the isogenic <italic>GATA6</italic><sup>corr/+</sup> line (as well as unmodified <italic>GATA6</italic><sup>1071delG+</sup> CRISPR-control clones) using CRISPR technology with Nickase-Cas9 according to previously established methods (<xref ref-type="bibr" rid="bib55">Ran et al., 2013</xref>). A pair of gRNA sequences were designed targeting opposing DNA strands surrounding the G deletion site. The gRNA 1 sequence was specifically designed to overlap the G deletion site to prevent Nickase-Cas9 activity on the WT <italic>GATA6</italic> allele. A 91 nucleotide (nt) length single-stranded DNA (ssDNA) repair template (Integrated DNA Technologies) was designed with 45 nt homology arms flanking the G mutation site, including a G to A silent mutation in the right homology arm and gRNA 2 recognition sequence to prevent Nickase-Cas9 activity after homology-directed repair (HDR). gRNAs 1 and 2 (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) were cloned into the pSpCas9n(BB)–2A-Puro (PX462) V2.0 plasmid (Addgene 62987) as described previously (<xref ref-type="bibr" rid="bib55">Ran et al., 2013</xref>). 2 million dissociated <italic>GATA6</italic> c.1071delG/+iPSCs were electroporated with 4 μg each gRNA-PX462 vector with 3 µL of 100 µmol/L ssDNA donor oligonucleotide (see <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) using the Neon Transfection System (two pulses at 1450 V for 20 ms, Invitrogen NEON1S) and plated on Matrigel coated dishes with mTESR Plus supplemented with 10 μM RI. A T7 endonuclease I assay (New England Biolabs M0302S) was performed to quantify indel frequency of gRNA pairs following PCR amplification (Phusion Hot Start Flex DNA Polymerase, New England Biolabs M0535L) and agarose gel electrophoresis from genomic DNA isolated 2–3 days after electroporation using the DNeasy Blood &amp; Tissue Kit (QIAGEN 69506). 24 hr after electroporation, the culture medium was replaced with mTESR Plus supplemented with 0.5 μg/mL puromycin (Sigma-Aldrich P8833) for antibiotic resistance selection for 48 hr. iPSCs were then dissociated with Accutase and plated at a low density (~3000 iPSCs per 10 cm plate) on Matrigel coated dishes with mTESR Plus medium (with 10 μM RI for the first 24 hr) and allowed to grow for about 2 weeks before iPSC colonies were manually isolated and plated into Matrigel coated 96-well plates and cultured with mTESR Plus. DNA was isolated from iPSC clones using QuickExtract DNA Extraction Solution (Biosearch Technologies QE09050), PCR amplification was performed using primers surrounding the mutation site (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>), and Sanger sequencing was performed to verify gene editing (GENEWIZ). Karyotyping was performed by the WiCell Research Institute (Madison, WI).</p></sec><sec id="s4-4"><title>hPSC cardiomyocyte differentiation</title><p>A monolayer cytokine-based cardiac differentiation protocol was adapted from previously established methods (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="bibr" rid="bib11">Dubois et al., 2011</xref>; <xref ref-type="bibr" rid="bib29">Kattman et al., 2011</xref>). Briefly, a ‘base medium’ for cardiac differentiation was prepared using RPMI 1640 (Thermo Fisher Scientific 22400089) supplemented with 0.5× B27 (Thermo Fisher Scientific 17504044), 0.5 mM 1-Thioglycerol (Sigma-Aldrich M6145), 50 μg/mL <sc>l</sc>-ascorbic acid (Sigma-Aldrich A4544), and 1× GlutaMAX (Thermo Fisher Scientific 35050061). The hPSCs were plated at ~4 × 10<sup>4</sup> cells/cm<sup>2</sup> and allowed to grow for 2 days before changing with ‘Day 0 medium’ consisting of the ‘base medium’ plus 20 ng/mL BMP4 (R&amp;D Systems 314BP-050), 30 ng/mL Activin A (R&amp;D Systems 338-AC-050), 5 ng/mL bFGF (R&amp;D Systems 233-FB-025), and 5 μL/mL Transferrin (Roche 10652202001). BMP4 was used at 10 ng/mL for iPSC differentiation. Approximately 55 hr later, the medium was changed with ‘Day 2 medium’ consisting of ‘base medium’ supplemented with 5 μM XAV-939 (Sigma-Aldrich X3004), 5 ng/mL VEGF (R&amp;D Systems 293-VE-050), and 5 μL/mL Transferrin. The culture medium was changed on days 4 and 6 of cardiac differentiation with ‘base medium’ supplemented with 5 ng/mL VEGF. From day 9 and later, the culture medium was changed with ‘base medium’ every 2–3 days. For a subset of experiments, 3 μM CHIR99021 (Stem Cell Technologies 72054) was included in the ‘Day 0 medium’ and/or the concentration of BMP4 was reduced to 5 ng/mL (<xref ref-type="fig" rid="fig6">Figure 6C and E</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C and D</xref>). An alternative CM differentiation protocol based on chemical manipulation of the WNT pathway (<xref ref-type="bibr" rid="bib35">Lian et al., 2012</xref>) was used for a subset of experiments (CHIR protocol, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B–E</xref>). For the CHIR protocol, hESCs were plated at ~4 × 10<sup>4</sup> cells/cm<sup>2</sup> and allowed to grow for 2 days in mTESR Plus before changing medium to RPMI 1640 with 1× B27 minus insulin (Thermo Fisher Scientific A1895601) and 6 μM CHIR99021 (Stem Cell Technologies 72054) for 24 hr. Medium was then changed to RPMI 1640 with 1× B27 minus insulin for another 24 hr, before changing medium on day 3 to RPMI 1640 with 1× B27 minus insulin and 5 mM IWP2 (Tocris 3533). On day 5, culture medium was changed to RPMI 1640 with 1× B27 minus insulin once more and starting on day 7 medium was changed to RPMI with 1× B27 every other day. CMs were purified using a lactate-selection protocol to prepare for immunocytochemistry by changing the differentiation medium on day 15 of the cytokine-based protocol to a lactate-selection medium consisting of RPMI 1640 lacking glucose (Thermo Fisher Scientific 11879020) supplemented with 5 mM sodium <sc>l</sc>-lactate (Sigma-Aldrich L7022), 213 μg/mL <sc>l</sc>-ascorbic acid, and 500 μg/mL Human Albumin (Sigma-Aldrich A9731). Lactate-selection medium was refreshed on day 17 of differentiation, after which the medium was restored to ‘base medium’ on day 19 and changed every 2–3 days prior to fixation.</p></sec><sec id="s4-5"><title>Flow cytometry</title><p>Cells were detached from culture plates using 0.5% Trypsin/0.5 mM EDTA (VWR 45000-664) or TrypLE Express Enzyme (Thermo Fisher Scientific 12605010) and resuspended in a FACS buffer consisting of PBS with 10% FBS (for cTnT staining) or 0.5% BSA (for live cell staining). Cells were fixed by pelleting at 300 × <italic>g</italic> and resuspended in 0.2% paraformaldehyde (PFA) for 25 min at room temperature (RT) before staining with primary antibody for cTNT (Thermo Fisher Scientific MA5-12960) in FACS buffer with 0.5% Saponin (Sigma-Aldrich S7900-25G) for 1 hr at RT, washed 3× in FACS buffer, and then stained for 1 hr at RT with FACS buffer plus Saponin containing secondary antibody (Invitrogen A21236). Live cells were used for staining the cell surface proteins KP by incubating with FACS buffer containing PE-conjugated KDR antibody (R&amp;D Systems FAB357P-100) and APC-conjugated PDGFRα antibody (R&amp;D Systems FAB1264A) or IgG control antibodies (R&amp;D Systems IC002P, IC002A) for 30 min at RT, and then stained with SYTOX Green Dead Cell Stain (Thermo Fisher Scientific S34860) in FACS buffer for 5 min at RT. BRACHYURY flow cytometry was performed using the Foxp3 Transcription Factor Staining Buffer Set (eBioscience 00-5523-00) according to the manufacturer’s protocol using a PE-conjugated BRACHYURY antibody (R&amp;D Systems IC2085P) or IgG control antibody (R&amp;D Systems IC108P). Flow cytometry was performed and analyzed using an Attune NxT Flow Cytometer (Thermo Fisher Scientific) for fixed cells and a BD-Accuri C6 Flow Cytometer (BD Biosciences) for live cells.</p></sec><sec id="s4-6"><title>RT-qPCR</title><p>RNA was isolated using the RNeasy Mini Kit (QIAGEN 74106) and reverse-transcribed using the SuperScript VILO cDNA Synthesis Kit (Invitrogen 11754250) according to the manufacturer’s protocols. The qPCR reaction was prepared by mixing cDNA with LightCycler 480 SYBR Green Master mix (Roche 04887-352-001) and primers listed in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>. RT-qPCR was performed using a LightCycler 480 Instrument II (Roche). Gene expression data was normalized to endogenous <italic>HPRT</italic> expression levels as a control for each sample.</p></sec><sec id="s4-7"><title>Western blotting</title><p>Whole-cell lysates were prepared using RIPA Lysis Buffer (Thermo Fisher Scientific 89900) supplemented with 1× Protease/Phosphatase Inhibitor Cocktail (Cell Signaling Technology 5872S) and 1× Benzonase (Millipore 70664-3). Protein was quantified using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific 23225) and electrophoresed on NuPAGE 4 to 12% Bis-Tris Gels (Invitrogen NP0335BOX) before transferring to PVDF membranes (Bio-Rad 162-0177). Blots were washed with 1× TBS with 0.1% Tween-20 (TBST) and blocked using 5% IgG-free BSA (VWR RLBSA50). Primary antibodies (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) were added to blocking buffer and stained overnight at 4°C. Secondary antibody staining was performed for 1 hr at RT using HRP-conjugated antibodies (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) in blocking buffer. Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific 32106) used to visualize proteins, and imaging was performed using a C-DiGit Blot Scanner (LI-COR) with ImageStudio (v5.2) and Adobe Photoshop (v25.9.1) software.</p></sec><sec id="s4-8"><title>Co-immunoprecipitation</title><p>Co-immunoprecipitation (co-IP) was performed using the Pierce Crosslink Magnetic IP/Co-IP Kit (Thermo Fisher Scientific 88805) according to the manufacturer’s protocol using cells at day 2 of cardiac differentiation. 7 μg of the GATA6 antibody (Cell Signaling Technology 5851) was used to cross-link to the Protein A/G Magnetic beads and 1 mg of protein was used for the IP reaction performed overnight at 4°C on a rotating platform. GATA6 Co-IP samples were electrophoresed on a gel and imaged as described for western blotting using 30 μg of protein lysate from the Co-IP used as an input control. <italic>GATA6</italic><sup>-/-</sup> cell samples served as a negative control.</p></sec><sec id="s4-9"><title>Immunocytochemistry and microscopy</title><p>Cells were fixed in tissue culture dishes with 4% PFA for 20 min at RT. Cells were washed in PBS and then blocked for 1 hr at RT with blocking buffer consisting of PBS with 10% FBS, 0.1% IgG-free BSA (Rockland Immunochemicals BSA-10), 0.1% Saponin, and 10% goat serum (Jackson ImmunoResearch Laboratories Inc 005-000-121). Cells were then stained with primary antibodies (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) diluted in blocking buffer (without goat serum) overnight at 4°C. Secondary antibody staining was performed in blocking buffer (without goat serum) for 1 hr at RT. Cells were stained with DAPI to visualize nuclei and imaged using a Zeiss LSM800 laser scanning confocal microscope with ZEN imaging software or a Zeiss Epifluorescence microscope with AxioVision software, and edited using Adobe Photoshop software (v25.9.1). Videos were taken using an Infinity5 Microscope Camera (Teledyne Lumenera) with Infinity Analyze software.</p></sec><sec id="s4-10"><title>Lentivirus production and infection</title><p><italic>LGR5</italic> full-length cDNA was first cloned into a DOX-inducible Lentiviral vector containing a GFP selection marker (CS-TRE-PRE-Ubc-tTA-I2G; <xref ref-type="bibr" rid="bib83">Yamaguchi et al., 2012</xref>) by performing PCR for LGR5 using WT cDNA samples from day 2 of cardiac differentiation and primers designed to incorporate the BsiWI and MfeI restriction enzyme recognition sites flanking LGR5 (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) to allow digestion and insertion into the CS-TRE-PRE-Ubc-tTA-I2G vector. <italic>LGR5</italic> sequence was validated by Sanger sequencing (GENEWIZ) using sequencing primers listed in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>. Lentivirus production was performed by transfecting 293T cells with the lentiviral expression vectors (LGR5 or EV control) and packaging plasmids using PEI. Transfected 293T cells were then allowed to produce lentivirus for 48 hr before the medium was collected, and the virus was concentrated using Lenti-X Concentrator (Takara 631231) according to the manufacturer’s protocol and resuspended in StemFlex medium. <italic>GATA6</italic><sup>-/-</sup> hESCs were infected with lentivirus by replacing medium with i<italic>LGR5</italic> or EV control (<xref ref-type="bibr" rid="bib33">Lan et al., 2021</xref>) lentivirus concentrate in StemFlex for 16 hr before changing to normal StemFlex and seeded for 2–3 days. Lentivirus-infected hESCs were then sorted based on GFP expression using FACS through the Weill Cornell Medicine Flow Cytometry Core Facility. Doxycline (DOX, Sigma-Aldrich D9891) was added from days 1–4 to induce expression of i<italic>LGR5</italic> or EV infected <italic>GATA6</italic><sup>-/-</sup> hESCs.</p></sec><sec id="s4-11"><title>RNA-seq</title><p>Total RNA was extracted from hESCs approximately 52 hr (day 2), 74 hr (day 3), or 5 days after starting the cardiac differentiation protocol using the RNeasy Mini Kit (QIAGEN 74106) from at least two independent biological replicates per sample. Total RNA integrity was verified using a 2100 Bioanalyzer (Agilent Technologies), and RNA concentrations were measured using the NanoDrop system (Thermo Fisher Scientific). Libraries were generated from days 2 and 5 RNA using the TruSeq RNA Library Prep Kit v2 (Illumina RS-122-2001) and day 3 RNA using the TruSeq Stranded mRNA Library Prep Kit (Illumina 20020594) according to the manufacturer’s instructions. Normalized cDNA libraries were pooled and sequenced on Illumina HiSeq4000 (days 2 and 5, single read) or Illumina NovaSeq 6000 (day 3, paired-end read) sequencing systems for 50 cycles through the Weill Cornell Medicine Genomics Resources Core Facility. The raw sequencing reads in BCL format were processed through bcl2fastq 2.19 (Illumina) for FASTQ conversion and demultiplexing. Day 2 and 5 RNA-seq alignment (GRChg19) and differential gene expression analysis was performed as described (<xref ref-type="bibr" rid="bib2">Anelli et al., 2017</xref>). Day 3 RNA-seq reads were aligned and mapped to the GRCh38 human reference genome using STAR (version 2.5.2; <xref ref-type="bibr" rid="bib10">Dobin et al., 2013</xref>) and transcriptome resconstruction was performed using Cufflinks (version 2.1.1, <ext-link ext-link-type="uri" xlink:href="http://cole-trapnell-lab.github.io/cufflinks/">http://cole-trapnell-lab.github.io/cufflinks/</ext-link>) after trimming adaptors with cutadapt (version 1.18, <ext-link ext-link-type="uri" xlink:href="https://cutadapt.readthedocs.io/en/v1.18/">https://cutadapt.readthedocs.io/en/v1.18/</ext-link>). The abundance of transcripts was measured with Cufflinks in Fragments Per Kilobase of exon model per Million mapped reads (FPKM) (<xref ref-type="bibr" rid="bib75">Trapnell et al., 2013</xref>; <xref ref-type="bibr" rid="bib74">Trapnell et al., 2010</xref>). Raw read counts per gene were extracted using HTSeq-count v0.11.2 (<xref ref-type="bibr" rid="bib1">Anders et al., 2015</xref>). Gene expression profiles were constructed for differential expression, cluster, and PCA with the DESeq2 package (<xref ref-type="bibr" rid="bib38">Love et al., 2014</xref>). For differential expression analysis, pairwise comparisons between two or more groups using parametric tests where read-counts follow a negative binomial distribution with a gene-specific dispersion parameter were performed. Corrected p-values were calculated based on the Benjamini–Hochberg method to adjust for multiple testing. GSEA was performed using GSEA 4.2.3 software (Broad Institute, Inc and Regents of the University of California) (<xref ref-type="bibr" rid="bib63">Subramanian et al., 2005</xref>) on RNA-seq gene lists ranked by log<sub>2</sub>(Fold Change) using the subcollection of biological process (BP) gene sets from the GO collection in the Human Molecular Signatures Database (MSigDB) (<xref ref-type="bibr" rid="bib4">Castanza et al., 2023</xref>), or using custom gene lists from published sequencing datasets as described in this article (<xref ref-type="bibr" rid="bib6">Chia et al., 2019</xref>; <xref ref-type="bibr" rid="bib31">Koh et al., 2016</xref>; <xref ref-type="bibr" rid="bib73">Tosic et al., 2019</xref>), and gene sets with a false discovery rate (FDR) <italic>q</italic>-value &lt; 0.25 and a nominal p-value&lt;0.05 were considered to be enriched significantly. GO analysis was performed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID, <ext-link ext-link-type="uri" xlink:href="https://davidbioinformatics.nih.gov/">david.ncifcrf.gov</ext-link>; <xref ref-type="bibr" rid="bib26">Huang et al., 2009</xref>; <xref ref-type="bibr" rid="bib59">Sherman et al., 2022</xref>) using the BP subcollection. Heatmaps were generated from normalized counts from selected gene lists using SRplot (<ext-link ext-link-type="uri" xlink:href="https://bioinformatics.com.cn/srplot">bioinformatics.com.cn/srplot</ext-link>; <xref ref-type="bibr" rid="bib69">Tang et al., 2023</xref>). DEGs were defined as p-value adjusted (p-adj)&lt;0.05 and log<sub>2</sub>(fold change)&gt;0.5, genes with a count below 50 for all samples were excluded.</p></sec><sec id="s4-12"><title>CUT&amp;RUN</title><p>500,000 H1-<italic>GATA6</italic><sup>+/+</sup> cells were harvested approximately 52 hr after starting the cardiac differentiation protocol, and CUT&amp;RUN was performed using the CUTANA ChIC/CUT&amp;RUN Kit (Epicypher 14-1048) according to the manufacturer’s protocol. Anti-GATA6 (n = 3 independent biological replicates) (Cell Signaling Technology 5851) and rabbit anti-IgG (n = 2 independent biological replicates) negative control (Epicypher 13-0042) antibodies were used at a 1:50 dilution (~0.5 μg). CUT&amp;RUN library preparation, sequencing, and SEACR-based analysis were performed by the Weill Cornell Medicine Epigenomics and Genomics Core Facilities. The DNA libraries were prepared with approximately 5 ng of CUT&amp;RUN enriched DNA using the NEBNext Ultra II DNA Library Prep Kit for Illumina (New England Biolabs E7645) and NEBNext Multiplex Oligos for Illumina (96 Unique Dual Index Primer Pairs) (New England Biolabs E6440); 14 PCR cycles were used to amplify the adaptor ligated target DNA. The libraries were clustered on a pair end flow cell and sequenced for 50 cycles on an Illumina NextSeq500 Sequencing System. FASTQ files were aligned to the GENCODE GRCh38 build of the human genome using bowtie2 with the –-dovetail parameter. The resulting BAM files were sorted and indexed using samtools and then converted to bedgraph format using bedtools. Peaks were subsequently called using SEACR to identify enrichment in target data by selecting the top 1% of regions by AUC (stringent threshold). The DiffBind R Bioconductor package was used to interrogate differential binding for GATA6 versus IgG controls, and the annotated significant nearby TSS gene list from the SEACR analysis was used for genomic peak distribution, GO analysis (as described for RNA-seq), and Venn diagram comparisons. Transcription factor motif enrichment analysis was performed using Basepair software with a CUT&amp;RUN Peaks, Motif (MACS2, HOMER) pipeline (basepairtech.com). EOMES CHIP-seq data from <xref ref-type="bibr" rid="bib70">Teo et al., 2011</xref> was aligned to GRChg38 using bowtie2 with Partek software (partek.com). CUT&amp;RUN and CHIP-seq data were visualized using Integrative Genomics Viewer (IGV) 2.16.2, and distal enhancer-like signatures (dELS) defined by the ENCODE Project (<xref ref-type="bibr" rid="bib44">Moore et al., 2020</xref>) were identified using the UCSC Genome Browser for hg38 (genome.ucsc.edu).</p></sec><sec id="s4-13"><title>RIME analysis</title><p>About ~50 million H1-<italic>GATA6</italic><sup>+/+</sup> cells at day 2 or 4 of cardiac differentiation were fixed with 1% formaldehyde (Electron Microscopy Sciences 15710) for 8 min at RT with gentle agitation. Fixation was quenched with 125 mM glycine (Bio-Rad 1610718) for 5 min at RT before cells were manually scraped, transferred to conical tubes, and pelleted at 800 × <italic>g</italic> at 4°C for 10 min. Pellets were resuspended in PBS with 0.5% IGEPAL CA-630 (Sigma-Aldrich I8896) and centrifuged again before resuspending in PBS-IGEPAL with 1 mM PMSF (Thermo Fisher Scientific 36978) and centrifuged one final time. Supernatant was then removed from pellets which were then snap frozen on dry ice and transferred to –80°C. RIME analysis was performed by Active Motif (Carlsbad, CA) according to published methods (<xref ref-type="bibr" rid="bib42">Mohammed et al., 2016</xref>) using 150 μg of chromatin per sample immunoprecipitating with anti-GATA6 (Cell Signaling Technology 5851) or anti-IgG control (Cell Signaling Technology 2729) antibodies (15 μg antibody per IP) and performing mass spectrometry with enriched GATA6 bound proteins defined as not present in the IgG controls and having a spectral count (the total number of all peptides detected) of at least 5 and &gt;1 unique peptides.</p></sec><sec id="s4-14"><title>Statistical analysis</title><p>Data is represented as the mean ± SEM from independent biological replicates (as indicated in figure legends). Graphing and statistical analysis were performed using GraphPad Prism v.10.2.3 software with two-tailed Student’s <italic>t</italic>-test when comparing two groups. One-way or two-way ANOVA was performed when comparing three or more groups, unless otherwise indicated.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Reviewing editor, eLife</p></fn><fn fn-type="COI-statement" id="conf3"><p>co-founder of OncoBeat, LLC</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Writing - original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Data curation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Resources</p></fn><fn fn-type="con" id="con8"><p>Resources</p></fn><fn fn-type="con" id="con9"><p>Resources</p></fn><fn fn-type="con" id="con10"><p>Resources</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Resources, Project administration</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Methodology, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>This study uses human pluripotent stem cell lines including embryonic stem cell lines that are listed and approved on the NIH human embryonic stem cell registry. The study was reviewed and approved by the Tri-Institutional Stem Cell Initiative ESCRO.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>GATA6-RIME-enriched proteins at day 2 or day 4 of cardiac differentiation.</title></caption><media xlink:href="elife-100797-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Cell lines, primer sequences, and antibodies used in this study.</title></caption><media xlink:href="elife-100797-supp2-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-100797-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All RNA-seq and CUT&amp;RUN data is available at the GEO repository and are publicly available as of the date of publication. The series accession numbers are GSE275685 and GSE275686.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Bisson</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>GATA6 regulates WNT and BMP programs to pattern precardiac mesoderm during the earliest stages of human cardiogenesis (CUT&amp;RUN)</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275685">GSE275685</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Bisson</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>GATA6 regulates WNT and BMP programs to pattern precardiac mesoderm during the earliest stages of human cardiogenesis (RNA-Seq)</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275686">GSE275686</pub-id></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset3"><person-group person-group-type="author"><name><surname>Loh</surname><given-names>KM</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Koh</surname><given-names>PW</given-names></name><name><surname>Deng</surname><given-names>TZ</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>Tsai</surname><given-names>JM</given-names></name><name><surname>Barkal</surname><given-names>AA</given-names></name><name><surname>Shen</surname><given-names>KY</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Morganti</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2016">2016</year><data-title>Mapping the Pairwise Choices Leading from Pluripotency to Human Bone, Heart, and Other Mesoderm Cell Types</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85066">GSE85066</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset4"><person-group person-group-type="author"><name><surname>Teo</surname><given-names>AK</given-names></name><name><surname>Arnold</surname><given-names>SJ</given-names></name><name><surname>Trotter</surname><given-names>MW</given-names></name><name><surname>Brown</surname><given-names>S</given-names></name><name><surname>Ang</surname><given-names>LT</given-names></name><name><surname>Chng</surname><given-names>Z</given-names></name><name><surname>Robertson</surname><given-names>EJ</given-names></name><name><surname>Dunn</surname><given-names>NR</given-names></name><name><surname>Vallier</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2011">2011</year><data-title>Pluripotency factors regulate definitive endoderm specification through eomesodermin</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77360">GSE77360</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset5"><person-group person-group-type="author"><name><surname>Tosic</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>GJ</given-names></name><name><surname>Pavlovic</surname><given-names>M</given-names></name><name><surname>Schroder</surname><given-names>CM</given-names></name><name><surname>Mersiowsky</surname><given-names>SL</given-names></name><name><surname>Barg</surname><given-names>M</given-names></name><name><surname>Hofherr</surname><given-names>A</given-names></name><name><surname>Probst</surname><given-names>S</given-names></name><name><surname>Kottgen</surname><given-names>M</given-names></name><name><surname>Hein</surname><given-names>L</given-names></name><name><surname>Arnold</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Eomes and Brachyury control pluripotency exit and germ-layer segregation by changing the chromatin state</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128466">GSE128466</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset6"><person-group person-group-type="author"><name><surname>Heslop</surname><given-names>JA</given-names></name><name><surname>Pournasr</surname><given-names>B</given-names></name><name><surname>Duncan</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Chromatin remodeling is restricted by transient GATA6 binding during iPSC differentiation to definitive endoderm</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE156021">GSE156021</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>JAB, DH, and TE conceived and planned the study. JAB generated most of the data, generated figures, and wrote the first manuscript draft. MG and KMB provided significant assistance and consult on experimental strategies and bioinformatics. RK and ZS generated and validated the iPSC lines. NdS and EY carried out experiments. ZS, KL, and DY generated and provided the hESC mutant lines prior to publication, and provided significant consult. WKC provided patient-derived fibroblasts used for iPSC generation. All authors edited and agreed on the final manuscript version. This work was supported by grants from the National Institutes of Health to TE (R35HL135778), DH (R01DK096239), and WKC (P01HD068250), an NIH postdoctoral fellowship to JAB (F32HL152575), the MSK Cancer Center Support Grant/Core Grant (P30CA008748), the Tri-Institutional Medical Scientist Training Program to KMB (T32GM007739) and additional grants (TE and DH) from the Starr Tri-I Stem Cell Initiative (2016–004) and the New York State Department of Health (NYSTEM, C029567). Thank you to Weill Cornell Medicine Genomics Resources Core Facility for assistance with RNA-seq and day 3 DEseq, and Piali Mukherjee and the Weill Cornell Medicine Epigenomics and Genomics Core Facilities for assistance with CUT&amp;RUN and SEACR-based analysis.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anders</surname><given-names>S</given-names></name><name><surname>Pyl</surname><given-names>PT</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>HTSeq--a Python framework to work with high-throughput sequencing data</article-title><source>Bioinformatics</source><volume>31</volume><fpage>166</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu638</pub-id><pub-id pub-id-type="pmid">25260700</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anelli</surname><given-names>V</given-names></name><name><surname>Villefranc</surname><given-names>JA</given-names></name><name><surname>Chhangawala</surname><given-names>S</given-names></name><name><surname>Martinez-McFaline</surname><given-names>R</given-names></name><name><surname>Riva</surname><given-names>E</given-names></name><name><surname>Nguyen</surname><given-names>A</given-names></name><name><surname>Verma</surname><given-names>A</given-names></name><name><surname>Bareja</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Scognamiglio</surname><given-names>T</given-names></name><name><surname>Elemento</surname><given-names>O</given-names></name><name><surname>Houvras</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression</article-title><source>eLife</source><volume>6</volume><elocation-id>e20728</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.20728</pub-id><pub-id pub-id-type="pmid">28350298</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brantjes</surname><given-names>H</given-names></name><name><surname>Roose</surname><given-names>J</given-names></name><name><surname>van De Wetering</surname><given-names>M</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>All Tcf HMG box transcription factors interact with Groucho-related co-repressors</article-title><source>Nucleic Acids Research</source><volume>29</volume><fpage>1410</fpage><lpage>1419</lpage><pub-id pub-id-type="doi">10.1093/nar/29.7.1410</pub-id><pub-id pub-id-type="pmid">11266540</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castanza</surname><given-names>AS</given-names></name><name><surname>Recla</surname><given-names>JM</given-names></name><name><surname>Eby</surname><given-names>D</given-names></name><name><surname>Thorvaldsdóttir</surname><given-names>H</given-names></name><name><surname>Bult</surname><given-names>CJ</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Extending support for mouse data in the Molecular Signatures Database (MSigDB)</article-title><source>Nature Methods</source><volume>20</volume><fpage>1619</fpage><lpage>1620</lpage><pub-id pub-id-type="doi">10.1038/s41592-023-02014-7</pub-id><pub-id pub-id-type="pmid">37704782</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chea</surname><given-names>S</given-names></name><name><surname>Kreger</surname><given-names>J</given-names></name><name><surname>Lopez-Burks</surname><given-names>ME</given-names></name><name><surname>MacLean</surname><given-names>AL</given-names></name><name><surname>Lander</surname><given-names>AD</given-names></name><name><surname>Calof</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Gastrulation-stage gene expression in Nipbl(+/-) mouse embryos foreshadows the development of syndromic birth defects</article-title><source>Science Advances</source><volume>10</volume><elocation-id>eadl4239</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.adl4239</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chia</surname><given-names>CY</given-names></name><name><surname>Madrigal</surname><given-names>P</given-names></name><name><surname>Denil</surname><given-names>S</given-names></name><name><surname>Martinez</surname><given-names>I</given-names></name><name><surname>Garcia-Bernardo</surname><given-names>J</given-names></name><name><surname>El-Khairi</surname><given-names>R</given-names></name><name><surname>Chhatriwala</surname><given-names>M</given-names></name><name><surname>Shepherd</surname><given-names>MH</given-names></name><name><surname>Hattersley</surname><given-names>AT</given-names></name><name><surname>Dunn</surname><given-names>NR</given-names></name><name><surname>Vallier</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>GATA6 cooperates with EOMES/SMAD2/3 to deploy the gene regulatory network governing human definitive endoderm and pancreas formation</article-title><source>Stem Cell Reports</source><volume>12</volume><fpage>57</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2018.12.003</pub-id><pub-id pub-id-type="pmid">30629940</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costello</surname><given-names>I</given-names></name><name><surname>Nowotschin</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Mould</surname><given-names>AW</given-names></name><name><surname>Hadjantonakis</surname><given-names>AK</given-names></name><name><surname>Bikoff</surname><given-names>EK</given-names></name><name><surname>Robertson</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Lhx1 functions together with Otx2, Foxa2, and Ldb1 to govern anterior mesendoderm, node, and midline development</article-title><source>Genes &amp; Development</source><volume>29</volume><fpage>2108</fpage><lpage>2122</lpage><pub-id pub-id-type="doi">10.1101/gad.268979.115</pub-id><pub-id pub-id-type="pmid">26494787</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuilliere-Dartigues</surname><given-names>P</given-names></name><name><surname>El-Bchiri</surname><given-names>J</given-names></name><name><surname>Krimi</surname><given-names>A</given-names></name><name><surname>Buhard</surname><given-names>O</given-names></name><name><surname>Fontanges</surname><given-names>P</given-names></name><name><surname>Fléjou</surname><given-names>JF</given-names></name><name><surname>Hamelin</surname><given-names>R</given-names></name><name><surname>Duval</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>TCF-4 isoforms absent in TCF-4 mutated MSI-H colorectal cancer cells colocalize with nuclear CtBP and repress TCF-4-mediated transcription</article-title><source>Oncogene</source><volume>25</volume><fpage>4441</fpage><lpage>4448</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1209471</pub-id><pub-id pub-id-type="pmid">16547505</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lau</surname><given-names>W</given-names></name><name><surname>Peng</surname><given-names>WC</given-names></name><name><surname>Gros</surname><given-names>P</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The R-spondin/Lgr5/Rnf43 module: regulator of Wnt signal strength</article-title><source>Genes &amp; Development</source><volume>28</volume><fpage>305</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1101/gad.235473.113</pub-id><pub-id pub-id-type="pmid">24532711</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Batut</surname><given-names>P</given-names></name><name><surname>Chaisson</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubois</surname><given-names>NC</given-names></name><name><surname>Craft</surname><given-names>AM</given-names></name><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Elliott</surname><given-names>DA</given-names></name><name><surname>Stanley</surname><given-names>EG</given-names></name><name><surname>Elefanty</surname><given-names>AG</given-names></name><name><surname>Gramolini</surname><given-names>A</given-names></name><name><surname>Keller</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells</article-title><source>Nature Biotechnology</source><volume>29</volume><fpage>1011</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1038/nbt.2005</pub-id><pub-id pub-id-type="pmid">22020386</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahed</surname><given-names>AC</given-names></name><name><surname>Gelb</surname><given-names>BD</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Genetics of congenital heart disease: the glass half empty</article-title><source>Circulation Research</source><volume>112</volume><fpage>707</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.112.300853</pub-id><pub-id pub-id-type="pmid">23410880</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>JB</given-names></name><name><surname>Pulakanti</surname><given-names>K</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Duncan</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>GATA6 is essential for endoderm formation from human pluripotent stem cells</article-title><source>Biology Open</source><volume>6</volume><fpage>1084</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1242/bio.026120</pub-id><pub-id pub-id-type="pmid">28606935</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funa</surname><given-names>NS</given-names></name><name><surname>Schachter</surname><given-names>KA</given-names></name><name><surname>Lerdrup</surname><given-names>M</given-names></name><name><surname>Ekberg</surname><given-names>J</given-names></name><name><surname>Hess</surname><given-names>K</given-names></name><name><surname>Dietrich</surname><given-names>N</given-names></name><name><surname>Honoré</surname><given-names>C</given-names></name><name><surname>Hansen</surname><given-names>K</given-names></name><name><surname>Semb</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>β-catenin regulates primitive streak induction through collaborative interactions with SMAD2/SMAD3 and OCT4</article-title><source>Cell Stem Cell</source><volume>16</volume><fpage>639</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2015.03.008</pub-id><pub-id pub-id-type="pmid">25921273</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gassmann</surname><given-names>M</given-names></name><name><surname>Casagranda</surname><given-names>F</given-names></name><name><surname>Orioli</surname><given-names>D</given-names></name><name><surname>Simon</surname><given-names>H</given-names></name><name><surname>Lai</surname><given-names>C</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Lemke</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor</article-title><source>Nature</source><volume>378</volume><fpage>390</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1038/378390a0</pub-id><pub-id pub-id-type="pmid">7477376</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gharibeh</surname><given-names>L</given-names></name><name><surname>Komati</surname><given-names>H</given-names></name><name><surname>Bossé</surname><given-names>Y</given-names></name><name><surname>Boodhwani</surname><given-names>M</given-names></name><name><surname>Heydarpour</surname><given-names>M</given-names></name><name><surname>Fortier</surname><given-names>M</given-names></name><name><surname>Hassanzadeh</surname><given-names>R</given-names></name><name><surname>Ngu</surname><given-names>J</given-names></name><name><surname>Mathieu</surname><given-names>P</given-names></name><name><surname>Body</surname><given-names>S</given-names></name><name><surname>Nemer</surname><given-names>M</given-names></name><collab>Bicuspid Aortic Valve Consortium</collab></person-group><year iso-8601-date="2018">2018</year><article-title>GATA6 regulates aortic valve remodeling, and its haploinsufficiency leads to right-left type bicuspid aortic valve</article-title><source>Circulation</source><volume>138</volume><fpage>1025</fpage><lpage>1038</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.029506</pub-id><pub-id pub-id-type="pmid">29567669</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gharibeh</surname><given-names>L</given-names></name><name><surname>Yamak</surname><given-names>A</given-names></name><name><surname>Whitcomb</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>A</given-names></name><name><surname>Joyal</surname><given-names>M</given-names></name><name><surname>Komati</surname><given-names>H</given-names></name><name><surname>Liang</surname><given-names>W</given-names></name><name><surname>Fiset</surname><given-names>C</given-names></name><name><surname>Nemer</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>GATA6 is a regulator of sinus node development and heart rhythm</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2007322118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2007322118</pub-id><pub-id pub-id-type="pmid">33443158</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>M</given-names></name><name><surname>Simaite</surname><given-names>D</given-names></name><name><surname>Kühnen</surname><given-names>P</given-names></name><name><surname>Heldmann</surname><given-names>M</given-names></name><name><surname>Spagnoli</surname><given-names>F</given-names></name><name><surname>Blankenstein</surname><given-names>O</given-names></name><name><surname>Hübner</surname><given-names>N</given-names></name><name><surname>Hussain</surname><given-names>K</given-names></name><name><surname>Raile</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Two novel GATA6 mutations cause childhood-onset diabetes mellitus, pancreas malformation and congenital heart disease</article-title><source>Hormone Research in Paediatrics</source><volume>79</volume><fpage>250</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1159/000348844</pub-id><pub-id pub-id-type="pmid">23635550</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>González</surname><given-names>F</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>Z-D</given-names></name><name><surname>Lelli</surname><given-names>K</given-names></name><name><surname>Verma</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>QV</given-names></name><name><surname>Huangfu</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells</article-title><source>Cell Stem Cell</source><volume>15</volume><fpage>215</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2014.05.018</pub-id><pub-id pub-id-type="pmid">24931489</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herchenröther</surname><given-names>A</given-names></name><name><surname>Gossen</surname><given-names>S</given-names></name><name><surname>Friedrich</surname><given-names>T</given-names></name><name><surname>Reim</surname><given-names>A</given-names></name><name><surname>Daus</surname><given-names>N</given-names></name><name><surname>Diegmüller</surname><given-names>F</given-names></name><name><surname>Leers</surname><given-names>J</given-names></name><name><surname>Sani</surname><given-names>HM</given-names></name><name><surname>Gerstner</surname><given-names>S</given-names></name><name><surname>Schwarz</surname><given-names>L</given-names></name><name><surname>Stellmacher</surname><given-names>I</given-names></name><name><surname>Szymkowiak</surname><given-names>LV</given-names></name><name><surname>Nist</surname><given-names>A</given-names></name><name><surname>Stiewe</surname><given-names>T</given-names></name><name><surname>Borggrefe</surname><given-names>T</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name><name><surname>Mackay</surname><given-names>JP</given-names></name><name><surname>Bartkuhn</surname><given-names>M</given-names></name><name><surname>Borchers</surname><given-names>A</given-names></name><name><surname>Lan</surname><given-names>J</given-names></name><name><surname>Hake</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The H2A.Z and NuRD associated protein HMG20A controls early head and heart developmental transcription programs</article-title><source>Nature Communications</source><volume>14</volume><elocation-id>472</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-023-36114-x</pub-id><pub-id pub-id-type="pmid">36709316</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heslop</surname><given-names>JA</given-names></name><name><surname>Pournasr</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>JT</given-names></name><name><surname>Duncan</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>GATA6 defines endoderm fate by controlling chromatin accessibility during differentiation of human-induced pluripotent stem cells</article-title><source>Cell Reports</source><volume>35</volume><elocation-id>109145</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109145</pub-id><pub-id pub-id-type="pmid">34010638</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heslop</surname><given-names>JA</given-names></name><name><surname>Pournasr</surname><given-names>B</given-names></name><name><surname>Duncan</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Chromatin remodeling is restricted by transient GATA6 binding during iPSC differentiation to definitive endoderm</article-title><source>iScience</source><volume>25</volume><elocation-id>104300</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2022.104300</pub-id><pub-id pub-id-type="pmid">35602939</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>JIE</given-names></name><name><surname>Kaplan</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The incidence of congenital heart disease</article-title><source>Journal of the American College of Cardiology</source><volume>39</volume><fpage>1890</fpage><lpage>1900</lpage><pub-id pub-id-type="doi">10.1016/s0735-1097(02)01886-7</pub-id><pub-id pub-id-type="pmid">12084585</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hota</surname><given-names>SK</given-names></name><name><surname>Johnson</surname><given-names>JR</given-names></name><name><surname>Verschueren</surname><given-names>E</given-names></name><name><surname>Thomas</surname><given-names>R</given-names></name><name><surname>Blotnick</surname><given-names>AM</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Pennacchio</surname><given-names>LA</given-names></name><name><surname>Krogan</surname><given-names>NJ</given-names></name><name><surname>Bruneau</surname><given-names>BG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Dynamic BAF chromatin remodeling complex subunit inclusion promotes temporally distinct gene expression programs in cardiogenesis</article-title><source>Development</source><volume>146</volume><elocation-id>dev174086</elocation-id><pub-id pub-id-type="doi">10.1242/dev.174086</pub-id><pub-id pub-id-type="pmid">30814119</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hota</surname><given-names>SK</given-names></name><name><surname>Rao</surname><given-names>KS</given-names></name><name><surname>Blair</surname><given-names>AP</given-names></name><name><surname>Khalilimeybodi</surname><given-names>A</given-names></name><name><surname>Hu</surname><given-names>KM</given-names></name><name><surname>Thomas</surname><given-names>R</given-names></name><name><surname>So</surname><given-names>K</given-names></name><name><surname>Kameswaran</surname><given-names>V</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Polacco</surname><given-names>BJ</given-names></name><name><surname>Desai</surname><given-names>RV</given-names></name><name><surname>Chatterjee</surname><given-names>N</given-names></name><name><surname>Hsu</surname><given-names>A</given-names></name><name><surname>Muncie</surname><given-names>JM</given-names></name><name><surname>Blotnick</surname><given-names>AM</given-names></name><name><surname>Winchester</surname><given-names>SAB</given-names></name><name><surname>Weinberger</surname><given-names>LS</given-names></name><name><surname>Hüttenhain</surname><given-names>R</given-names></name><name><surname>Kathiriya</surname><given-names>IS</given-names></name><name><surname>Krogan</surname><given-names>NJ</given-names></name><name><surname>Saucerman</surname><given-names>JJ</given-names></name><name><surname>Bruneau</surname><given-names>BG</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Brahma safeguards canalization of cardiac mesoderm differentiation</article-title><source>Nature</source><volume>602</volume><fpage>129</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-04336-y</pub-id><pub-id pub-id-type="pmid">35082446</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>DW</given-names></name><name><surname>Sherman</surname><given-names>BT</given-names></name><name><surname>Lempicki</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title><source>Nature Protocols</source><volume>4</volume><fpage>44</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1038/nprot.2008.211</pub-id><pub-id pub-id-type="pmid">19131956</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivanovitch</surname><given-names>K</given-names></name><name><surname>Soro-Barrio</surname><given-names>P</given-names></name><name><surname>Chakravarty</surname><given-names>P</given-names></name><name><surname>Jones</surname><given-names>RA</given-names></name><name><surname>Bell</surname><given-names>DM</given-names></name><name><surname>Mousavy Gharavy</surname><given-names>SN</given-names></name><name><surname>Stamataki</surname><given-names>D</given-names></name><name><surname>Delile</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>JC</given-names></name><name><surname>Briscoe</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Ventricular, atrial, and outflow tract heart progenitors arise from spatially and molecularly distinct regions of the primitive streak</article-title><source>PLOS Biology</source><volume>19</volume><elocation-id>e3001200</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3001200</pub-id><pub-id pub-id-type="pmid">33999917</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jha</surname><given-names>R</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Gentillon</surname><given-names>C</given-names></name><name><surname>Preininger</surname><given-names>MK</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Downregulation of LGR5 expression inhibits cardiomyocyte differentiation and potentiates endothelial differentiation from human pluripotent stem cells</article-title><source>Stem Cell Reports</source><volume>9</volume><fpage>513</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2017.07.006</pub-id><pub-id pub-id-type="pmid">28793247</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kattman</surname><given-names>SJ</given-names></name><name><surname>Witty</surname><given-names>AD</given-names></name><name><surname>Gagliardi</surname><given-names>M</given-names></name><name><surname>Dubois</surname><given-names>NC</given-names></name><name><surname>Niapour</surname><given-names>M</given-names></name><name><surname>Hotta</surname><given-names>A</given-names></name><name><surname>Ellis</surname><given-names>J</given-names></name><name><surname>Keller</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines</article-title><source>Cell Stem Cell</source><volume>8</volume><fpage>228</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2010.12.008</pub-id><pub-id pub-id-type="pmid">21295278</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimelman</surname><given-names>D</given-names></name><name><surname>Griffin</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Vertebrate mesendoderm induction and patterning</article-title><source>Current Opinion in Genetics &amp; Development</source><volume>10</volume><fpage>350</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1016/s0959-437x(00)00095-2</pub-id><pub-id pub-id-type="pmid">10889062</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>PW</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>Barkal</surname><given-names>AA</given-names></name><name><surname>Morganti</surname><given-names>RM</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name><name><surname>Ang</surname><given-names>LT</given-names></name><name><surname>Kundaje</surname><given-names>A</given-names></name><name><surname>Loh</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>An atlas of transcriptional, chromatin accessibility, and surface marker changes in human mesoderm development</article-title><source>Scientific Data</source><volume>3</volume><elocation-id>160109</elocation-id><pub-id pub-id-type="doi">10.1038/sdata.2016.109</pub-id><pub-id pub-id-type="pmid">27996962</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laco</surname><given-names>F</given-names></name><name><surname>Woo</surname><given-names>TL</given-names></name><name><surname>Zhong</surname><given-names>Q</given-names></name><name><surname>Szmyd</surname><given-names>R</given-names></name><name><surname>Ting</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>FJ</given-names></name><name><surname>Chai</surname><given-names>CLL</given-names></name><name><surname>Reuveny</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Oh</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Unraveling the inconsistencies of cardiac differentiation efficiency induced by the GSK3β inhibitor CHIR99021 in human pluripotent stem cells</article-title><source>Stem Cell Reports</source><volume>10</volume><fpage>1851</fpage><lpage>1866</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2018.03.023</pub-id><pub-id pub-id-type="pmid">29706502</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>Y</given-names></name><name><surname>Banks</surname><given-names>KM</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Verma</surname><given-names>N</given-names></name><name><surname>Dixon</surname><given-names>GR</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Ding</surname><given-names>B</given-names></name><name><surname>Elemento</surname><given-names>O</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Huangfu</surname><given-names>D</given-names></name><name><surname>Evans</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Stage-specific regulation of DNA methylation by TET enzymes during human cardiac differentiation</article-title><source>Cell Reports</source><volume>37</volume><elocation-id>110095</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.110095</pub-id><pub-id pub-id-type="pmid">34879277</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>I</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Sham</surname><given-names>MH</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>SWI/SNF protein component BAF250a regulates cardiac progenitor cell differentiation by modulating chromatin accessibility during second heart field development</article-title><source>The Journal of Biological Chemistry</source><volume>287</volume><fpage>24255</fpage><lpage>24262</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.365080</pub-id><pub-id pub-id-type="pmid">22621927</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lian</surname><given-names>X</given-names></name><name><surname>Hsiao</surname><given-names>C</given-names></name><name><surname>Wilson</surname><given-names>G</given-names></name><name><surname>Zhu</surname><given-names>K</given-names></name><name><surname>Hazeltine</surname><given-names>LB</given-names></name><name><surname>Azarin</surname><given-names>SM</given-names></name><name><surname>Raval</surname><given-names>KK</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Kamp</surname><given-names>TJ</given-names></name><name><surname>Palecek</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling</article-title><source>PNAS</source><volume>109</volume><fpage>E1848</fpage><lpage>E1857</lpage><pub-id pub-id-type="doi">10.1073/pnas.1200250109</pub-id><pub-id pub-id-type="pmid">22645348</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lickert</surname><given-names>H</given-names></name><name><surname>Takeuchi</surname><given-names>JK</given-names></name><name><surname>Von Both</surname><given-names>I</given-names></name><name><surname>Walls</surname><given-names>JR</given-names></name><name><surname>McAuliffe</surname><given-names>F</given-names></name><name><surname>Adamson</surname><given-names>SL</given-names></name><name><surname>Henkelman</surname><given-names>RM</given-names></name><name><surname>Wrana</surname><given-names>JL</given-names></name><name><surname>Rossant</surname><given-names>J</given-names></name><name><surname>Bruneau</surname><given-names>BG</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Baf60c is essential for function of BAF chromatin remodelling complexes in heart development</article-title><source>Nature</source><volume>432</volume><fpage>107</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1038/nature03071</pub-id><pub-id pub-id-type="pmid">15525990</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loh</surname><given-names>KM</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Koh</surname><given-names>PW</given-names></name><name><surname>Deng</surname><given-names>TZ</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>Tsai</surname><given-names>JM</given-names></name><name><surname>Barkal</surname><given-names>AA</given-names></name><name><surname>Shen</surname><given-names>KY</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Morganti</surname><given-names>RM</given-names></name><name><surname>Shyh-Chang</surname><given-names>N</given-names></name><name><surname>Fernhoff</surname><given-names>NB</given-names></name><name><surname>George</surname><given-names>BM</given-names></name><name><surname>Wernig</surname><given-names>G</given-names></name><name><surname>Salomon</surname><given-names>REA</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Vogel</surname><given-names>H</given-names></name><name><surname>Epstein</surname><given-names>JA</given-names></name><name><surname>Kundaje</surname><given-names>A</given-names></name><name><surname>Talbot</surname><given-names>WS</given-names></name><name><surname>Beachy</surname><given-names>PA</given-names></name><name><surname>Ang</surname><given-names>LT</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mapping the pairwise choices leading from pluripotency to human bone, heart, and other mesoderm cell types</article-title><source>Cell</source><volume>166</volume><fpage>451</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.06.011</pub-id><pub-id pub-id-type="pmid">27419872</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millard</surname><given-names>CJ</given-names></name><name><surname>Varma</surname><given-names>N</given-names></name><name><surname>Saleh</surname><given-names>A</given-names></name><name><surname>Morris</surname><given-names>K</given-names></name><name><surname>Watson</surname><given-names>PJ</given-names></name><name><surname>Bottrill</surname><given-names>AR</given-names></name><name><surname>Fairall</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>CJ</given-names></name><name><surname>Schwabe</surname><given-names>JWR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The structure of the core NuRD repression complex provides insights into its interaction with chromatin</article-title><source>eLife</source><volume>5</volume><elocation-id>e13941</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.13941</pub-id><pub-id pub-id-type="pmid">27098840</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miquerol</surname><given-names>L</given-names></name><name><surname>Kelly</surname><given-names>RG</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Organogenesis of the vertebrate heart</article-title><source>Wiley Interdisciplinary Reviews. Developmental Biology</source><volume>2</volume><fpage>17</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1002/wdev.68</pub-id><pub-id pub-id-type="pmid">23799628</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mittal</surname><given-names>P</given-names></name><name><surname>Roberts</surname><given-names>CWM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The SWI/SNF complex in cancer - biology, biomarkers and therapy</article-title><source>Nature Reviews. Clinical Oncology</source><volume>17</volume><fpage>435</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1038/s41571-020-0357-3</pub-id><pub-id pub-id-type="pmid">32303701</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammed</surname><given-names>H</given-names></name><name><surname>Taylor</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>GD</given-names></name><name><surname>Papachristou</surname><given-names>EK</given-names></name><name><surname>Carroll</surname><given-names>JS</given-names></name><name><surname>D’Santos</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) for analysis of chromatin complexes</article-title><source>Nature Protocols</source><volume>11</volume><fpage>316</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1038/nprot.2016.020</pub-id><pub-id pub-id-type="pmid">26797456</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molkentin</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>38949</fpage><lpage>38952</lpage><pub-id pub-id-type="doi">10.1074/jbc.R000029200</pub-id><pub-id pub-id-type="pmid">11042222</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>JE</given-names></name><name><surname>Purcaro</surname><given-names>MJ</given-names></name><name><surname>Pratt</surname><given-names>HE</given-names></name><name><surname>Epstein</surname><given-names>CB</given-names></name><name><surname>Shoresh</surname><given-names>N</given-names></name><name><surname>Adrian</surname><given-names>J</given-names></name><name><surname>Kawli</surname><given-names>T</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Kaul</surname><given-names>R</given-names></name><name><surname>Halow</surname><given-names>J</given-names></name><name><surname>Van Nostrand</surname><given-names>EL</given-names></name><name><surname>Freese</surname><given-names>P</given-names></name><name><surname>Gorkin</surname><given-names>DU</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Mackiewicz</surname><given-names>M</given-names></name><name><surname>Pauli-Behn</surname><given-names>F</given-names></name><name><surname>Williams</surname><given-names>BA</given-names></name><name><surname>Mortazavi</surname><given-names>A</given-names></name><name><surname>Keller</surname><given-names>CA</given-names></name><name><surname>Zhang</surname><given-names>XO</given-names></name><name><surname>Elhajjajy</surname><given-names>SI</given-names></name><name><surname>Huey</surname><given-names>J</given-names></name><name><surname>Dickel</surname><given-names>DE</given-names></name><name><surname>Snetkova</surname><given-names>V</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Rivera-Mulia</surname><given-names>JC</given-names></name><name><surname>Rozowsky</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Chhetri</surname><given-names>SB</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Victorsen</surname><given-names>A</given-names></name><name><surname>White</surname><given-names>KP</given-names></name><name><surname>Visel</surname><given-names>A</given-names></name><name><surname>Yeo</surname><given-names>GW</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name><name><surname>Lécuyer</surname><given-names>E</given-names></name><name><surname>Gilbert</surname><given-names>DM</given-names></name><name><surname>Dekker</surname><given-names>J</given-names></name><name><surname>Rinn</surname><given-names>J</given-names></name><name><surname>Mendenhall</surname><given-names>EM</given-names></name><name><surname>Ecker</surname><given-names>JR</given-names></name><name><surname>Kellis</surname><given-names>M</given-names></name><name><surname>Klein</surname><given-names>RJ</given-names></name><name><surname>Noble</surname><given-names>WS</given-names></name><name><surname>Kundaje</surname><given-names>A</given-names></name><name><surname>Guigó</surname><given-names>R</given-names></name><name><surname>Farnham</surname><given-names>PJ</given-names></name><name><surname>Cherry</surname><given-names>JM</given-names></name><name><surname>Myers</surname><given-names>RM</given-names></name><name><surname>Ren</surname><given-names>B</given-names></name><name><surname>Graveley</surname><given-names>BR</given-names></name><name><surname>Gerstein</surname><given-names>MB</given-names></name><name><surname>Pennacchio</surname><given-names>LA</given-names></name><name><surname>Snyder</surname><given-names>MP</given-names></name><name><surname>Bernstein</surname><given-names>BE</given-names></name><name><surname>Wold</surname><given-names>B</given-names></name><name><surname>Hardison</surname><given-names>RC</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name><name><surname>Stamatoyannopoulos</surname><given-names>JA</given-names></name><name><surname>Weng</surname><given-names>Z</given-names></name><collab>ENCODE Project Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Expanded encyclopaedias of DNA elements in the human and mouse genomes</article-title><source>Nature</source><volume>583</volume><fpage>699</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2493-4</pub-id><pub-id pub-id-type="pmid">32728249</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrisey</surname><given-names>EE</given-names></name><name><surname>Tang</surname><given-names>Z</given-names></name><name><surname>Sigrist</surname><given-names>K</given-names></name><name><surname>Lu</surname><given-names>MM</given-names></name><name><surname>Jiang</surname><given-names>F</given-names></name><name><surname>Ip</surname><given-names>HS</given-names></name><name><surname>Parmacek</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>GATA6 regulates HNF4 and is required for differentiation of visceral endoderm in the mouse embryo</article-title><source>Genes &amp; Development</source><volume>12</volume><fpage>3579</fpage><lpage>3590</lpage><pub-id pub-id-type="doi">10.1101/gad.12.22.3579</pub-id><pub-id pub-id-type="pmid">9832509</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mummery</surname><given-names>CL</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ng</surname><given-names>ES</given-names></name><name><surname>Elliott</surname><given-names>DA</given-names></name><name><surname>Elefanty</surname><given-names>AG</given-names></name><name><surname>Kamp</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview</article-title><source>Circulation Research</source><volume>111</volume><fpage>344</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.110.227512</pub-id><pub-id pub-id-type="pmid">22821908</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murry</surname><given-names>CE</given-names></name><name><surname>Keller</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development</article-title><source>Cell</source><volume>132</volume><fpage>661</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.02.008</pub-id><pub-id pub-id-type="pmid">18295582</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patient</surname><given-names>RK</given-names></name><name><surname>McGhee</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The GATA family (vertebrates and invertebrates)</article-title><source>Current Opinion in Genetics &amp; Development</source><volume>12</volume><fpage>416</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1016/s0959-437x(02)00319-2</pub-id><pub-id pub-id-type="pmid">12100886</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pekkanen-Mattila</surname><given-names>M</given-names></name><name><surname>Kerkelä</surname><given-names>E</given-names></name><name><surname>Tanskanen</surname><given-names>JMA</given-names></name><name><surname>Pietilä</surname><given-names>M</given-names></name><name><surname>Pelto-Huikko</surname><given-names>M</given-names></name><name><surname>Hyttinen</surname><given-names>J</given-names></name><name><surname>Skottman</surname><given-names>H</given-names></name><name><surname>Suuronen</surname><given-names>R</given-names></name><name><surname>Aalto-Setälä</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Substantial variation in the cardiac differentiation of human embryonic stem cell lines derived and propagated under the same conditions--a comparison of multiple cell lines</article-title><source>Annals of Medicine</source><volume>41</volume><fpage>360</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1080/07853890802609542</pub-id><pub-id pub-id-type="pmid">19165643</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perl</surname><given-names>E</given-names></name><name><surname>Waxman</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Reiterative mechanisms of retinoic acid signaling during vertebrate heart development</article-title><source>Journal of Developmental Biology</source><volume>7</volume><elocation-id>11</elocation-id><pub-id pub-id-type="doi">10.3390/jdb7020011</pub-id><pub-id pub-id-type="pmid">31151214</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterkin</surname><given-names>T</given-names></name><name><surname>Gibson</surname><given-names>A</given-names></name><name><surname>Loose</surname><given-names>M</given-names></name><name><surname>Patient</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The roles of GATA-4, -5 and -6 in vertebrate heart development</article-title><source>Seminars in Cell &amp; Developmental Biology</source><volume>16</volume><fpage>83</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2004.10.003</pub-id><pub-id pub-id-type="pmid">15659343</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterkin</surname><given-names>T</given-names></name><name><surname>Gibson</surname><given-names>A</given-names></name><name><surname>Patient</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Redundancy and evolution of GATA factor requirements in development of the myocardium</article-title><source>Developmental Biology</source><volume>311</volume><fpage>623</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2007.08.018</pub-id><pub-id pub-id-type="pmid">17869240</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Probst</surname><given-names>S</given-names></name><name><surname>Tosic</surname><given-names>J</given-names></name><name><surname>Schwan</surname><given-names>C</given-names></name><name><surname>Grün</surname><given-names>D</given-names></name><name><surname>Arnold</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Spatiotemporal sequence of mesoderm and endoderm lineage segregation during mouse gastrulation</article-title><source>Development</source><volume>148</volume><elocation-id>dev193789</elocation-id><pub-id pub-id-type="doi">10.1242/dev.193789</pub-id><pub-id pub-id-type="pmid">33199445</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prummel</surname><given-names>KD</given-names></name><name><surname>Nieuwenhuize</surname><given-names>S</given-names></name><name><surname>Mosimann</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The lateral plate mesoderm</article-title><source>Development</source><volume>147</volume><elocation-id>dev175059</elocation-id><pub-id pub-id-type="doi">10.1242/dev.175059</pub-id><pub-id pub-id-type="pmid">32561665</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ran</surname><given-names>FA</given-names></name><name><surname>Hsu</surname><given-names>PD</given-names></name><name><surname>Wright</surname><given-names>J</given-names></name><name><surname>Agarwala</surname><given-names>V</given-names></name><name><surname>Scott</surname><given-names>DA</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Genome engineering using the CRISPR-Cas9 system</article-title><source>Nature Protocols</source><volume>8</volume><fpage>2281</fpage><lpage>2308</lpage><pub-id pub-id-type="doi">10.1038/nprot.2013.143</pub-id><pub-id pub-id-type="pmid">24157548</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahara</surname><given-names>M</given-names></name><name><surname>Santoro</surname><given-names>F</given-names></name><name><surname>Sohlmér</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Witman</surname><given-names>N</given-names></name><name><surname>Leung</surname><given-names>CY</given-names></name><name><surname>Mononen</surname><given-names>M</given-names></name><name><surname>Bylund</surname><given-names>K</given-names></name><name><surname>Gruber</surname><given-names>P</given-names></name><name><surname>Chien</surname><given-names>KR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Population and single-cell analysis of human cardiogenesis reveals unique lgr5 ventricular progenitors in embryonic outflow tract</article-title><source>Developmental Cell</source><volume>48</volume><fpage>475</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2019.01.005</pub-id><pub-id pub-id-type="pmid">30713072</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Seidman</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Transcription factor haploinsufficiency: when half a loaf is not enough</article-title><source>The Journal of Clinical Investigation</source><volume>109</volume><fpage>451</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1172/JCI15043</pub-id><pub-id pub-id-type="pmid">11854316</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Wasson</surname><given-names>LK</given-names></name><name><surname>Willcox</surname><given-names>JA</given-names></name><name><surname>Morton</surname><given-names>SU</given-names></name><name><surname>Gorham</surname><given-names>JM</given-names></name><name><surname>DeLaughter</surname><given-names>DM</given-names></name><name><surname>Neyazi</surname><given-names>M</given-names></name><name><surname>Schmid</surname><given-names>M</given-names></name><name><surname>Agarwal</surname><given-names>R</given-names></name><name><surname>Jang</surname><given-names>MY</given-names></name><name><surname>Toepfer</surname><given-names>CN</given-names></name><name><surname>Ward</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Pereira</surname><given-names>AC</given-names></name><name><surname>DePalma</surname><given-names>SR</given-names></name><name><surname>Tai</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Conner</surname><given-names>D</given-names></name><name><surname>Bernstein</surname><given-names>D</given-names></name><name><surname>Gelb</surname><given-names>BD</given-names></name><name><surname>Chung</surname><given-names>WK</given-names></name><name><surname>Goldmuntz</surname><given-names>E</given-names></name><name><surname>Porter</surname><given-names>G</given-names></name><name><surname>Tristani-Firouzi</surname><given-names>M</given-names></name><name><surname>Srivastava</surname><given-names>D</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name><collab>Pediatric Cardiac Genomics Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title><italic>GATA6</italic> mutations in hiPSCs inform mechanisms for maldevelopment of the heart, pancreas, and diaphragm</article-title><source>eLife</source><volume>9</volume><elocation-id>e53278</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.53278</pub-id><pub-id pub-id-type="pmid">33054971</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherman</surname><given-names>BT</given-names></name><name><surname>Hao</surname><given-names>M</given-names></name><name><surname>Qiu</surname><given-names>J</given-names></name><name><surname>Jiao</surname><given-names>X</given-names></name><name><surname>Baseler</surname><given-names>MW</given-names></name><name><surname>Lane</surname><given-names>HC</given-names></name><name><surname>Imamichi</surname><given-names>T</given-names></name><name><surname>Chang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update)</article-title><source>Nucleic Acids Research</source><volume>50</volume><fpage>W216</fpage><lpage>W221</lpage><pub-id pub-id-type="doi">10.1093/nar/gkac194</pub-id><pub-id pub-id-type="pmid">35325185</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>ZD</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Amin</surname><given-names>S</given-names></name><name><surname>Verma</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>QV</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Soh</surname><given-names>CL</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Evans</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Huangfu</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genome editing in hPSCs reveals GATA6 haploinsufficiency and a genetic interaction with GATA4 in human pancreatic development</article-title><source>Cell Stem Cell</source><volume>20</volume><fpage>675</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2017.01.001</pub-id><pub-id pub-id-type="pmid">28196600</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Wasson</surname><given-names>LK</given-names></name><name><surname>Dorr</surname><given-names>KM</given-names></name><name><surname>Robbe</surname><given-names>ZL</given-names></name><name><surname>Wilczewski</surname><given-names>CM</given-names></name><name><surname>Hepperla</surname><given-names>AJ</given-names></name><name><surname>Davis</surname><given-names>IJ</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Conlon</surname><given-names>FL</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>CHD4 and SMYD1 repress common transcriptional programs in the developing heart</article-title><source>Development</source><volume>151</volume><elocation-id>dev202505</elocation-id><pub-id pub-id-type="doi">10.1242/dev.202505</pub-id><pub-id pub-id-type="pmid">38619323</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stavish</surname><given-names>D</given-names></name><name><surname>Böiers</surname><given-names>C</given-names></name><name><surname>Price</surname><given-names>C</given-names></name><name><surname>Frith</surname><given-names>TJR</given-names></name><name><surname>Halliwell</surname><given-names>J</given-names></name><name><surname>Saldaña-Guerrero</surname><given-names>I</given-names></name><name><surname>Wray</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>J</given-names></name><name><surname>Carr</surname><given-names>J</given-names></name><name><surname>James</surname><given-names>C</given-names></name><name><surname>Barbaric</surname><given-names>I</given-names></name><name><surname>Andrews</surname><given-names>PW</given-names></name><name><surname>Enver</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Generation and trapping of a mesoderm biased state of human pluripotency</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>4989</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-18727-8</pub-id><pub-id pub-id-type="pmid">33020476</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sulahian</surname><given-names>R</given-names></name><name><surname>Casey</surname><given-names>F</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Qian</surname><given-names>ZR</given-names></name><name><surname>Shin</surname><given-names>H</given-names></name><name><surname>Ogino</surname><given-names>S</given-names></name><name><surname>Weir</surname><given-names>BA</given-names></name><name><surname>Vazquez</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>XS</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Bass</surname><given-names>AJ</given-names></name><name><surname>Chan</surname><given-names>V</given-names></name><name><surname>Shivdasani</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>An integrative analysis reveals functional targets of GATA6 transcriptional regulation in gastric cancer</article-title><source>Oncogene</source><volume>33</volume><fpage>5637</fpage><lpage>5648</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.517</pub-id><pub-id pub-id-type="pmid">24317510</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Kolligs</surname><given-names>FT</given-names></name><name><surname>Hottiger</surname><given-names>MO</given-names></name><name><surname>Mosavin</surname><given-names>R</given-names></name><name><surname>Fearon</surname><given-names>ER</given-names></name><name><surname>Nabel</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Regulation of beta -catenin transformation by the p300 transcriptional coactivator</article-title><source>PNAS</source><volume>97</volume><fpage>12613</fpage><lpage>12618</lpage><pub-id pub-id-type="doi">10.1073/pnas.220158597</pub-id><pub-id pub-id-type="pmid">11050151</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tada</surname><given-names>S</given-names></name><name><surname>Era</surname><given-names>T</given-names></name><name><surname>Furusawa</surname><given-names>C</given-names></name><name><surname>Sakurai</surname><given-names>H</given-names></name><name><surname>Nishikawa</surname><given-names>S</given-names></name><name><surname>Kinoshita</surname><given-names>M</given-names></name><name><surname>Nakao</surname><given-names>K</given-names></name><name><surname>Chiba</surname><given-names>T</given-names></name><name><surname>Nishikawa</surname><given-names>SI</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Characterization of mesendoderm: a diverging point of the definitive endoderm and mesoderm in embryonic stem cell differentiation culture</article-title><source>Development</source><volume>132</volume><fpage>4363</fpage><lpage>4374</lpage><pub-id pub-id-type="doi">10.1242/dev.02005</pub-id><pub-id pub-id-type="pmid">16141227</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takaku</surname><given-names>M</given-names></name><name><surname>Grimm</surname><given-names>SA</given-names></name><name><surname>Shimbo</surname><given-names>T</given-names></name><name><surname>Perera</surname><given-names>L</given-names></name><name><surname>Menafra</surname><given-names>R</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name><name><surname>Archer</surname><given-names>TK</given-names></name><name><surname>Machida</surname><given-names>S</given-names></name><name><surname>Kurumizaka</surname><given-names>H</given-names></name><name><surname>Wade</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>GATA3-dependent cellular reprogramming requires activation-domain dependent recruitment of a chromatin remodeler</article-title><source>Genome Biology</source><volume>17</volume><elocation-id>36</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-016-0897-0</pub-id><pub-id pub-id-type="pmid">26922637</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>M</given-names></name><name><surname>Kanki</surname><given-names>Y</given-names></name><name><surname>Masumoto</surname><given-names>H</given-names></name><name><surname>Funakoshi</surname><given-names>S</given-names></name><name><surname>Hatani</surname><given-names>T</given-names></name><name><surname>Fukushima</surname><given-names>H</given-names></name><name><surname>Izumi-Taguchi</surname><given-names>A</given-names></name><name><surname>Matsui</surname><given-names>Y</given-names></name><name><surname>Shimamura</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>Y</given-names></name><name><surname>Yamashita</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Identification of cardiomyocyte-fated progenitors from human-induced pluripotent stem cells marked with CD82</article-title><source>Cell Reports</source><volume>22</volume><fpage>546</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.12.057</pub-id><pub-id pub-id-type="pmid">29320747</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Zeng</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>SRplot: A free online platform for data visualization and graphing</article-title><source>PLOS ONE</source><volume>18</volume><elocation-id>e0294236</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0294236</pub-id><pub-id pub-id-type="pmid">37943830</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teo</surname><given-names>AKK</given-names></name><name><surname>Arnold</surname><given-names>SJ</given-names></name><name><surname>Trotter</surname><given-names>MWB</given-names></name><name><surname>Brown</surname><given-names>S</given-names></name><name><surname>Ang</surname><given-names>LT</given-names></name><name><surname>Chng</surname><given-names>Z</given-names></name><name><surname>Robertson</surname><given-names>EJ</given-names></name><name><surname>Dunn</surname><given-names>NR</given-names></name><name><surname>Vallier</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Pluripotency factors regulate definitive endoderm specification through eomesodermin</article-title><source>Genes &amp; Development</source><volume>25</volume><fpage>238</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1101/gad.607311</pub-id><pub-id pub-id-type="pmid">21245162</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>L</given-names></name><name><surname>Goss</surname><given-names>AM</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Lepore</surname><given-names>JJ</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Schwartz</surname><given-names>RJ</given-names></name><name><surname>Patel</surname><given-names>V</given-names></name><name><surname>Cohen</surname><given-names>ED</given-names></name><name><surname>Morrisey</surname><given-names>EE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Characterization and in vivo pharmacological rescue of a Wnt2-Gata6 pathway required for cardiac inflow tract development</article-title><source>Developmental Cell</source><volume>18</volume><fpage>275</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2010.01.008</pub-id><pub-id pub-id-type="pmid">20159597</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiyaboonchai</surname><given-names>A</given-names></name><name><surname>Cardenas-Diaz</surname><given-names>FL</given-names></name><name><surname>Ying</surname><given-names>L</given-names></name><name><surname>Maguire</surname><given-names>JA</given-names></name><name><surname>Sim</surname><given-names>X</given-names></name><name><surname>Jobaliya</surname><given-names>C</given-names></name><name><surname>Gagne</surname><given-names>AL</given-names></name><name><surname>Kishore</surname><given-names>S</given-names></name><name><surname>Stanescu</surname><given-names>DE</given-names></name><name><surname>Hughes</surname><given-names>N</given-names></name><name><surname>De Leon</surname><given-names>DD</given-names></name><name><surname>French</surname><given-names>DL</given-names></name><name><surname>Gadue</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>GATA6 plays an important role in the induction of human definitive endoderm, development of the pancreas, and functionality of pancreatic β cells</article-title><source>Stem Cell Reports</source><volume>8</volume><fpage>589</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2016.12.026</pub-id><pub-id pub-id-type="pmid">28196690</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tosic</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>G-J</given-names></name><name><surname>Pavlovic</surname><given-names>M</given-names></name><name><surname>Schröder</surname><given-names>CM</given-names></name><name><surname>Mersiowsky</surname><given-names>S-L</given-names></name><name><surname>Barg</surname><given-names>M</given-names></name><name><surname>Hofherr</surname><given-names>A</given-names></name><name><surname>Probst</surname><given-names>S</given-names></name><name><surname>Köttgen</surname><given-names>M</given-names></name><name><surname>Hein</surname><given-names>L</given-names></name><name><surname>Arnold</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Eomes and Brachyury control pluripotency exit and germ-layer segregation by changing the chromatin state</article-title><source>Nature Cell Biology</source><volume>21</volume><fpage>1518</fpage><lpage>1531</lpage><pub-id pub-id-type="doi">10.1038/s41556-019-0423-1</pub-id><pub-id pub-id-type="pmid">31792383</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Williams</surname><given-names>BA</given-names></name><name><surname>Pertea</surname><given-names>G</given-names></name><name><surname>Mortazavi</surname><given-names>A</given-names></name><name><surname>Kwan</surname><given-names>G</given-names></name><name><surname>van Baren</surname><given-names>MJ</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name><name><surname>Wold</surname><given-names>BJ</given-names></name><name><surname>Pachter</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation</article-title><source>Nature Biotechnology</source><volume>28</volume><fpage>511</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1038/nbt.1621</pub-id><pub-id pub-id-type="pmid">20436464</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Hendrickson</surname><given-names>DG</given-names></name><name><surname>Sauvageau</surname><given-names>M</given-names></name><name><surname>Goff</surname><given-names>L</given-names></name><name><surname>Rinn</surname><given-names>JL</given-names></name><name><surname>Pachter</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Differential analysis of gene regulation at transcript resolution with RNA-seq</article-title><source>Nature Biotechnology</source><volume>31</volume><fpage>46</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1038/nbt.2450</pub-id><pub-id pub-id-type="pmid">23222703</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueno</surname><given-names>S</given-names></name><name><surname>Weidinger</surname><given-names>G</given-names></name><name><surname>Osugi</surname><given-names>T</given-names></name><name><surname>Kohn</surname><given-names>AD</given-names></name><name><surname>Golob</surname><given-names>JL</given-names></name><name><surname>Pabon</surname><given-names>L</given-names></name><name><surname>Reinecke</surname><given-names>H</given-names></name><name><surname>Moon</surname><given-names>RT</given-names></name><name><surname>Murry</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Biphasic role for Wnt/beta-catenin signaling in cardiac specification in zebrafish and embryonic stem cells</article-title><source>PNAS</source><volume>104</volume><fpage>9685</fpage><lpage>9690</lpage><pub-id pub-id-type="doi">10.1073/pnas.0702859104</pub-id><pub-id pub-id-type="pmid">17522258</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valenta</surname><given-names>T</given-names></name><name><surname>Lukas</surname><given-names>J</given-names></name><name><surname>Korinek</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>HMG box transcription factor TCF-4’s interaction with CtBP1 controls the expression of the Wnt target Axin2/Conductin in human embryonic kidney cells</article-title><source>Nucleic Acids Research</source><volume>31</volume><fpage>2369</fpage><lpage>2380</lpage><pub-id pub-id-type="doi">10.1093/nar/gkg346</pub-id><pub-id pub-id-type="pmid">12711682</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Berlo</surname><given-names>JH</given-names></name><name><surname>Elrod</surname><given-names>JW</given-names></name><name><surname>van den Hoogenhof</surname><given-names>MMG</given-names></name><name><surname>York</surname><given-names>AJ</given-names></name><name><surname>Aronow</surname><given-names>BJ</given-names></name><name><surname>Duncan</surname><given-names>SA</given-names></name><name><surname>Molkentin</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The transcription factor GATA-6 regulates pathological cardiac hypertrophy</article-title><source>Circulation Research</source><volume>107</volume><fpage>1032</fpage><lpage>1040</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.110.220764</pub-id><pub-id pub-id-type="pmid">20705924</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>SD</given-names></name><name><surname>Mayeuf-Louchart</surname><given-names>A</given-names></name><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>Brzezinski</surname><given-names>JA</given-names></name><name><surname>Miyagawa-Tomita</surname><given-names>S</given-names></name><name><surname>Kelly</surname><given-names>RG</given-names></name><name><surname>Buckingham</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Prdm1 functions in the mesoderm of the second heart field, where it interacts genetically with Tbx1, during outflow tract morphogenesis in the mouse embryo</article-title><source>Human Molecular Genetics</source><volume>23</volume><fpage>5087</fpage><lpage>5101</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddu232</pub-id><pub-id pub-id-type="pmid">24821700</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>XJ</given-names></name><name><surname>Xin</surname><given-names>YF</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>ZM</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>RG</given-names></name><name><surname>Fang</surname><given-names>WY</given-names></name><name><surname>Wang</surname><given-names>XZ</given-names></name><name><surname>Yang</surname><given-names>YQ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Novel GATA6 mutations associated with congenital ventricular septal defect or tetralogy of fallot</article-title><source>DNA and Cell Biology</source><volume>31</volume><fpage>1610</fpage><lpage>1617</lpage><pub-id pub-id-type="doi">10.1089/dna.2012.1814</pub-id><pub-id pub-id-type="pmid">23020118</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>BK</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>McCray</surname><given-names>A</given-names></name><name><surname>Hawk</surname><given-names>WH</given-names></name><name><surname>Deary</surname><given-names>LT</given-names></name><name><surname>Sugiarto</surname><given-names>NW</given-names></name><name><surname>LaCroix</surname><given-names>IS</given-names></name><name><surname>Gerber</surname><given-names>SA</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Cooperation of chromatin remodeling SWI/SNF complex and pioneer factor AP-1 shapes 3D enhancer landscapes</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>30</volume><fpage>10</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1038/s41594-022-00880-x</pub-id><pub-id pub-id-type="pmid">36522426</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woudstra</surname><given-names>OI</given-names></name><name><surname>Ahuja</surname><given-names>S</given-names></name><name><surname>Bokma</surname><given-names>JP</given-names></name><name><surname>Bouma</surname><given-names>BJ</given-names></name><name><surname>Mulder</surname><given-names>BJM</given-names></name><name><surname>Christoffels</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Origins and consequences of congenital heart defects affecting the right ventricle</article-title><source>Cardiovascular Research</source><volume>113</volume><fpage>1509</fpage><lpage>1520</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvx155</pub-id><pub-id pub-id-type="pmid">28957538</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamaguchi</surname><given-names>T</given-names></name><name><surname>Hamanaka</surname><given-names>S</given-names></name><name><surname>Kamiya</surname><given-names>A</given-names></name><name><surname>Okabe</surname><given-names>M</given-names></name><name><surname>Kawarai</surname><given-names>M</given-names></name><name><surname>Wakiyama</surname><given-names>Y</given-names></name><name><surname>Umino</surname><given-names>A</given-names></name><name><surname>Hayama</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Kato-Itoh</surname><given-names>M</given-names></name><name><surname>Masaki</surname><given-names>H</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Yamazaki</surname><given-names>S</given-names></name><name><surname>Nakauchi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Development of an all-in-one inducible lentiviral vector for gene specific analysis of reprogramming</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e41007</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0041007</pub-id><pub-id pub-id-type="pmid">22815895</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Gomez-Garcia</surname><given-names>J</given-names></name><name><surname>Funakoshi</surname><given-names>S</given-names></name><name><surname>Tran</surname><given-names>T</given-names></name><name><surname>Fernandes</surname><given-names>I</given-names></name><name><surname>Bader</surname><given-names>GD</given-names></name><name><surname>Laflamme</surname><given-names>MA</given-names></name><name><surname>Keller</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Modeling human multi-lineage heart field development with pluripotent stem cells</article-title><source>Cell Stem Cell</source><volume>29</volume><fpage>1382</fpage><lpage>1401</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2022.08.007</pub-id><pub-id pub-id-type="pmid">36055193</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Bennett</surname><given-names>JT</given-names></name><name><surname>Wynn</surname><given-names>J</given-names></name><name><surname>Carvill</surname><given-names>GL</given-names></name><name><surname>Cheung</surname><given-names>YH</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Mychaliska</surname><given-names>GB</given-names></name><name><surname>Azarow</surname><given-names>KS</given-names></name><name><surname>Crombleholme</surname><given-names>TM</given-names></name><name><surname>Chung</surname><given-names>DH</given-names></name><name><surname>Potoka</surname><given-names>D</given-names></name><name><surname>Warner</surname><given-names>BW</given-names></name><name><surname>Bucher</surname><given-names>B</given-names></name><name><surname>Lim</surname><given-names>FY</given-names></name><name><surname>Pietsch</surname><given-names>J</given-names></name><name><surname>Stolar</surname><given-names>C</given-names></name><name><surname>Aspelund</surname><given-names>G</given-names></name><name><surname>Arkovitz</surname><given-names>MS</given-names></name><name><surname>Mefford</surname><given-names>H</given-names></name><name><surname>Chung</surname><given-names>WK</given-names></name><collab>University of Washington Center for Mendelian Genomics</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Whole exome sequencing identifies de novo mutations in GATA6 associated with congenital diaphragmatic hernia</article-title><source>Journal of Medical Genetics</source><volume>51</volume><fpage>197</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1136/jmedgenet-2013-101989</pub-id><pub-id pub-id-type="pmid">24385578</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>E</given-names></name><name><surname>Hong</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Fu</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Targeted sequencing identifies novel GATA6 variants in a large cohort of patients with conotruncal heart defects</article-title><source>Gene</source><volume>641</volume><fpage>341</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2017.10.083</pub-id><pub-id pub-id-type="pmid">29101065</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom"><italic>GATA6</italic></td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">GATA binding protein 6</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom"><italic>LRG5</italic></td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">Leucine-rich repeat containing G protein-coupled receptor 5</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Escherichia coli</italic>)</td><td align="left" valign="bottom">One Shot TOP10</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">C404006</td><td align="left" valign="bottom">Chemically competent cells</td></tr><tr><td align="left" valign="bottom">Cell line <italic>(H. sapiens)</italic></td><td align="left" valign="bottom">H1 (NIH:0043)</td><td align="left" valign="bottom">WiCell</td><td align="left" valign="bottom">WA01</td><td align="left" valign="bottom">Human embryonic stem cells</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">Dermal fibroblast (normal, adult)</td><td align="left" valign="bottom">PCGC study patient</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Used to generate iPSC line</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">iPSC line</td><td align="left" valign="bottom">Mutant GATA6 allelle c1071 delG</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">See Data availability</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">iPSC line</td><td align="left" valign="bottom">Allele reverted to wildtype</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">See Data availability</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="char" char="." valign="bottom">293T</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-11268</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">CF1 mouse embryonic fibroblasts</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">A34180</td><td align="left" valign="bottom">Primary cells</td></tr><tr><td align="left" valign="bottom">Transfected construct</td><td align="left" valign="bottom">pSpCas9n(BB)-2A-Puro (PX462) V2.0</td><td align="left" valign="bottom">Addgene</td><td align="char" char="." valign="bottom">62987</td><td align="left" valign="bottom">CRISPR vector for Nickase-Cas9</td></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">CS-TRE-PRE-Ubc-tTA-I2G</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Derived from 198058</td><td align="left" valign="bottom">Lentiviral vector for inducible expression of LGR5</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-human GATA6 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="char" char="." valign="bottom">5851</td><td align="left" valign="bottom">WB (1:1000)<break/>RIME: 15 ug</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-IgG control (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="char" char="." valign="bottom">2729</td><td align="left" valign="bottom">WB (1:1000)<break/>RIME: 15 ug</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">See <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref> for a full list of antibodies</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom">Integrated DNA Technologies</td><td align="left" valign="bottom">See <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref> for a full list of guide RNAs</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR primers</td><td align="left" valign="bottom">Integrated DNA Technologies</td><td align="left" valign="bottom">See <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref> for a full list of qPCR primers</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Donor sequence to correct mutant allele</td><td align="left" valign="bottom">Integrated DNA Technologies</td><td align="left" valign="bottom"><named-content content-type="sequence">GGCGCCACTGACGCCTGCCTGGCCCGCCGGACCCTTCGAGACCCCGGTGCTGCACAGCCTACAGAGCCGCGCCGGAGCCCCGCTCCCGGTG</named-content></td><td align="left" valign="bottom">See <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref></td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">bFGF</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="char" char="hyphen" valign="bottom">233-FB-025</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Activin A</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="char" char="hyphen" valign="bottom">338-AC-050</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">BMP4</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="char" char="." valign="bottom">314BP-050</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">VEGF</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="char" char="hyphen" valign="bottom">293-VE-050</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">CytoTune-iPS 2.0 Sendai Reprogramming Kit</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">A16517</td><td align="left" valign="bottom">For generating iPSC lines</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">T7 endonuclease I assay</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">M0302S</td><td align="left" valign="bottom">For indel detection</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">QuickExtract DNA Extraction Solution</td><td align="left" valign="bottom">Biosearch Technologies</td><td align="left" valign="bottom">QE09050</td><td align="left" valign="bottom">DNA purification</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">SuperScript VILO cDNA Synthesis Kit</td><td align="left" valign="bottom">Invitrogen</td><td align="char" char="." valign="bottom">11754250</td><td align="left" valign="bottom">cDNA generation</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">LightCycler 480 SYBR Green Master mix</td><td align="left" valign="bottom">Roche</td><td align="char" char="hyphen" valign="bottom">04887-352-001</td><td align="left" valign="bottom">qPCR assays</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Pierce Crosslink Magnetic IP/Co-IP Kit</td><td align="left" valign="bottom">Thermo Fisher</td><td align="char" char="." valign="bottom">88805</td><td align="left" valign="bottom">Co-IP assays</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">TruSeq RNA Library Prep Kit v2</td><td align="left" valign="bottom">Illumina</td><td align="left" valign="bottom">RS-122-2001</td><td align="left" valign="bottom">Sequencing libraries</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">TruSeq Stranded mRNA Library Prep Kit</td><td align="left" valign="bottom">Illumina</td><td align="char" char="." valign="bottom">20020594</td><td align="left" valign="bottom">Sequencing libraries</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NEBNext Ultra II DNA Library Prep Kit</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">E7645</td><td align="left" valign="bottom">CUT&amp;RUN libraries</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NEBNext Multiplex Oligos for Illumina</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">E6440</td><td align="left" valign="bottom">CUT&amp;RUN libraries</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">CUTANA ChIC/CUT&amp;RUN Kit</td><td align="left" valign="bottom">Epicypher</td><td align="char" char="." valign="bottom">14-1048</td><td align="left" valign="bottom">CUT&amp;RUN</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">LookOut Mycoplasma PCR Detection Kit</td><td align="left" valign="bottom">Stem Cell Technologies</td><td align="char" char="." valign="bottom">1000276</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Pierce BCA Protein Assay Kit</td><td align="left" valign="bottom">Thermo Fisher</td><td align="char" char="." valign="bottom">23225</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Pierce ECL Western Blotting Substrate</td><td align="left" valign="bottom">Thermo Fisher</td><td align="char" char="." valign="bottom">32106</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Y-27632</td><td align="left" valign="bottom">Selleckchem</td><td align="left" valign="bottom">S1049</td><td align="left" valign="bottom">ROCK inhibitor</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Puromycin</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">P8833</td><td align="left" valign="bottom">Selection</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">XAV-939</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">X3004</td><td align="left" valign="bottom">Tankyrase inhibitor</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">CHIR99021</td><td align="left" valign="bottom">Stem Cell Technologies</td><td align="char" char="." valign="bottom">72054</td><td align="left" valign="bottom">GSK-3 inhibitor</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">IWP2</td><td align="left" valign="bottom">Tocris</td><td align="char" char="." valign="bottom">3533</td><td align="left" valign="bottom">Porcupine inhibitor</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ImageStudio</td><td align="left" valign="bottom">LI-COR</td><td align="left" valign="bottom">V5.2</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Photoshop</td><td align="left" valign="bottom">Adobe</td><td align="left" valign="bottom">V25.9.1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">bcl2fastq</td><td align="left" valign="bottom">Illumina</td><td align="left" valign="bottom">V2.19</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">STAR</td><td align="left" valign="bottom">Github</td><td align="left" valign="bottom">V2.5.2</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Cufflinks</td><td align="left" valign="bottom">Github</td><td align="left" valign="bottom">V2.1.1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">HTSeq-count</td><td align="left" valign="bottom">Github</td><td align="left" valign="bottom">V0.11.2</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GSEA</td><td align="left" valign="bottom">Broad Institute</td><td align="left" valign="bottom">V4.2.3</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Gene Ontology</td><td align="left" valign="bottom">Database for Annotation, <break/>Visualization, and Integrated Discovery</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://davidbioinformatics.nih.gov/">David.ncifcrf.gov</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">SRplot</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://bioinformatics.com.cn/srplot">bioinformatics.com.cn/srplot</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Prism</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom">v.10.2.3</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Matrigel</td><td align="left" valign="bottom">Corning</td><td align="left" valign="bottom">BD354277</td><td align="left" valign="bottom">Reagent</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">StemFlex Medium</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">A3349401</td><td align="left" valign="bottom">Medium</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">mTESR Plus Medium</td><td align="left" valign="bottom">Stem Cell Technologies</td><td align="char" char="." valign="bottom">1000276</td><td align="left" valign="bottom">Medium</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">mTESR1 medium</td><td align="left" valign="bottom">Stem Cell Technologies</td><td align="char" char="." valign="bottom">85850</td><td align="left" valign="bottom">Medium</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Accutase Cell Detachment Solution</td><td align="left" valign="bottom">Selleckchem</td><td align="left" valign="bottom">S1049</td><td align="left" valign="bottom">Reagent</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">DMEM/F12 medium</td><td align="left" valign="bottom">VWR</td><td align="char" char="." valign="bottom">16777-255</td><td align="left" valign="bottom">Medium</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">KnockOut serum replacement medium</td><td align="left" valign="bottom">Thermo Fisher</td><td align="char" char="." valign="bottom">10828010</td><td align="left" valign="bottom">Medium</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">RPMI 1640 medium</td><td align="left" valign="bottom">Thermo Fisher</td><td align="char" char="." valign="bottom">2240089</td><td align="left" valign="bottom">Medium</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">B27</td><td align="left" valign="bottom">Thermo Fisher</td><td align="char" char="." valign="bottom">17504044</td><td align="left" valign="bottom">Medium additive</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">B27-insulin</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">A1895601</td><td align="left" valign="bottom">Medium additive</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Sodium <sc>l</sc>-lactate</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">L7022</td><td align="left" valign="bottom">Medium additive</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Human albumin</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">A9731</td><td align="left" valign="bottom">Medium additive</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">1-Thioglycerol</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">M6145</td><td align="left" valign="bottom">Medium additive</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">GlutaMAX</td><td align="left" valign="bottom">Thermo Fisher</td><td align="char" char="." valign="bottom">35050061</td><td align="left" valign="bottom">Medium additive</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Transferrin</td><td align="left" valign="bottom">Roche</td><td align="char" char="." valign="bottom">10652202001</td><td align="left" valign="bottom">Medium additive</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Trypsin/EDTA</td><td align="left" valign="bottom">VWR</td><td align="char" char="." valign="bottom">45000-664</td><td align="left" valign="bottom">Reagent</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">TrypLE Express Enzyme</td><td align="left" valign="bottom">Thermo Fisher</td><td align="char" char="." valign="bottom">12605010</td><td align="left" valign="bottom">Reagent</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Saponin</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">S7900-25G</td><td align="left" valign="bottom">Reagent</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">RIPA Lysis Buffer</td><td align="left" valign="bottom">Thermo Fisher</td><td align="char" char="." valign="bottom">89900</td><td align="left" valign="bottom">Reagent</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Protease/Phosphatase Inhibitor Cocktail</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="char" char="." valign="bottom">5872S</td><td align="left" valign="bottom">Reagent</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Lenti-X concentrator</td><td align="left" valign="bottom">Takara</td><td align="char" char="." valign="bottom">631231</td><td align="left" valign="bottom">Assay kit</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Formaldehyde</td><td align="left" valign="bottom">Electron Microscopy Services</td><td align="char" char="." valign="bottom">15710</td><td align="left" valign="bottom">Chemical</td></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.100797.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Scott</surname><given-names>Ian C</given-names></name><role specific-use="editor">Reviewing Editor</role></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This <bold>important</bold> study investigates the function of a critical regulator of human early cardiac development. The <bold>convincing</bold> examination of GATA6 function is thorough and well-executed. The study will be of interest to scientists working on how the human heart acquires its identity.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.100797.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This is a comprehensive study that clearly and deeply investigates the function of GATA6 in human early cardiac development.</p><p>Strengths:</p><p>This study combines hESC engineering, differentiation, detailed gene expression, genome occupancy, and pathway modulation to elucidate the role of GATA6 in early cardiac differentiation. The work is carefully executed and the results support the conclusions. The use of publicly available data is well integrated throughout the manuscript. The RIME experiments are excellent.</p><p>Weaknesses:</p><p>Much has been known about GATA6 in mesendoderm development, and this is acknowledged by the authors.</p><p>Comments on revised version:</p><p>The authors have addressed my comments appropriately.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.100797.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This manuscript by Bisson et al describes the role GATA6 to regulate cardiac progenitor cell (CPC) specification and cardiomyocyte (CM) generation using human embryonic stem cells (hESCs). The authors found that GATA6 loss-of-function hESC exhibit early defects in mesendoderm and lateral mesoderm patterning stages. Using RNA-seq and CUT&amp;RUN assays the genes of the Wnt and BMP programs were found to be affected by the loss of GATA6 expression. Modulating Wnt and BMP during early cardiac differentiation can partially rescue CPC and CM defects in GATA6 hetero- and homozygous mutant hESCs.</p><p>Strengths:</p><p>The studies performed were rigorous and the rationale for the experimental designed were logical. The results obtained were clear and supports the conclusions that the authors made regarding the role of GATA6 on Wnt and BMP pathway gene expression.</p><p>Weaknesses:</p><p>Given the wealth of studies that have been performed in this research area previously, the amount of new information provided in this study is relatively modest. Nevertheless, the results and quite clear and should make a strong contribution to the field.</p><p>Comments on revised version:</p><p>The authors have addressed the prior request to assess genes expression representing each stage of development/differentiation from mesoderm to cardiac progenitor to cardiomyocytes and confirmed that the differentiation defect lies at the cardiac progenitor and cardiomyocyte stages and not in mesodermal differentiation. This work has significantly improved the robustness of the study.</p></body></sub-article><sub-article article-type="referee-report" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.100797.3.sa3</article-id><title-group><article-title>Reviewer #3 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>In this study, Bison et al. analyzed the role of the GATA6 transcription factor in patterning the early mesoderm and generating cardiomyocytes, using human embryonic stem cell differentiation assays and patient-derived hiPSCs with heart defects associated with mutations in the GATA6 gene. They identified a novel role for GATA6 in regulating genes involved in the WNT and BMP pathways. Modulation of the WNT and BMP pathways partially rescue early cardiac mesoderm defects in GATA6 mutant hESCs. These results provide significant insights into how GATA6 loss-of-function and heterozygous mutations contribute to heart defects.</p><p>Comments on revised version:</p><p>The authors have addressed all the concerns, using new data and modifications to the text to further strengthen the manuscript.</p></body></sub-article><sub-article article-type="author-comment" id="sa4"><front-stub><article-id pub-id-type="doi">10.7554/eLife.100797.3.sa4</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bisson</surname><given-names>Joseph A</given-names></name><role specific-use="author">Author</role><aff><institution>Weill Cornell Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Gordillo</surname><given-names>Miriam</given-names></name><role specific-use="author">Author</role><aff><institution>Weill Cornell Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Ritu</given-names></name><role specific-use="author">Author</role><aff><institution>Gladstone Institutes</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>de Silva</surname><given-names>Neranjan</given-names></name><role specific-use="author">Author</role><aff><institution>Weill Cornell Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Ellen</given-names></name><role specific-use="author">Author</role><aff><institution>Weill Cornell Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Banks</surname><given-names>Kelly M</given-names></name><role specific-use="author">Author</role><aff><institution>Weill Cornell Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Zhong-Dong</given-names></name><role specific-use="author">Author</role><aff><institution>Memorial Sloan Kettering Cancer Center</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Kihyun</given-names></name><role specific-use="author">Author</role><aff><institution>Ewha Womans University</institution><addr-line><named-content content-type="city">Seoul</named-content></addr-line><country>Republic of Korea</country></aff></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Dapeng</given-names></name><role specific-use="author">Author</role><aff><institution>Sloan Kettering Institute</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Chung</surname><given-names>Wendy K</given-names></name><role specific-use="author">Author</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00dvg7y05</institution-id><institution>Boston Children's Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Huangfu</surname><given-names>Danwei</given-names></name><role specific-use="author">Author</role><aff><institution>Sloan Kettering Institute</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Evans</surname><given-names>Todd</given-names></name><role specific-use="author">Author</role><aff><institution>Weill Cornell Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public review):</bold></p><p>Summary:</p><p>This is a comprehensive study that clearly and deeply investigates the function of GATA6 in human early cardiac development.</p><p>Strengths:</p><p>This study combines hESC engineering, differentiation, detailed gene expression, genome occupancy, and pathway modulation to elucidate the role of GATA6 in early cardiac differentiation. The work is carefully executed and the results support the conclusions. The use of publicly available data is well integrated throughout the manuscript. The RIME experiments are excellent.</p><p>Weaknesses:</p><p>Much has been known about GATA6 in mesendoderm development, and this is acknowledged by the authors.</p></disp-quote><p>We appreciate the comments and have tried to highlight both the early role of GATA6 in cardiac progenitor biology as well as the haploinsufficiency for relevance to human congenital heart disease, which we believe adds value to other recent published work, among others Sharma et al. eLife 2020.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>Summary:</p><p>This manuscript by Bisson et al describes the role of GATA6 to regulate cardiac progenitor cell (CPC) specification and cardiomyocyte (CM) generation using human embryonic stem cells (hESCs). The authors found that GATA6 loss-of-function hESC exhibits early defects in mesendoderm and lateral mesoderm patterning stages. Using RNA-seq and CUT&amp;RUN assays the genes of the Wnt and BMP programs were found to be affected by the loss of GATA6 expression. Modulating Wnt and BMP during early cardiac differentiation can partially rescue CPC and CM defects in GATA6 hetero- and homozygous mutant hESCs.</p><p>Strengths:</p><p>The studies performed were rigorous and the rationale for the experimental design was logical. The results obtained were clear and supported the conclusions that the authors made regarding the role of GATA6 on Wnt and BMP pathway gene expression.</p><p>Weaknesses:</p><p>Given the wealth of studies that have been performed in this research area previously, the amount of new information provided in this study is relatively modest. Nevertheless, the results and quite clear and should make a strong contribution to the field.</p></disp-quote><p>Likewise for reviewer 2, we appreciate the comments and have tried to highlight both the early role of GATA6 in cardiac progenitor biology as well as the haploinsufficiency for relevance to human congenital heart disease.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public review):</bold></p><p>In this study, Bison et al. analyzed the role of the GATA6 transcription factor in patterning the early mesoderm and generating cardiomyocytes, using human embryonic stem cell differentiation assays and patient-derived hiPSCs with heart defects associated with mutations in the GATA6 gene. They identified a novel role for GATA6 in regulating genes involved in the WNT and BMP pathways -findings not previously noted in earlier analyses of GATA6 mutant hiPSCs during early cardiac mesoderm specification (Sharma et al., 2020). Modulation of the WNT and BMP pathways may partially rescue early cardiac mesoderm defects in GATA6 mutant hESCs. These results provide significant insights into how GATA6 loss-of-function and heterozygous mutations contribute to heart defects.</p><p>I have the following comments:</p><p>(1) Throughout the manuscript, Bison et al. alternate between different protocols to generate cardiomyocytes, which creates some confusion (e.g., Figure 1 vs. Supplemental Figure 2A). The authors should provide a clear justification for using alternative protocols.</p></disp-quote><p>We agree and clarified this issue in the revision (p. 6). The reviewer is correct that there are two widely used protocols for directed differentiation of PSCs to cardiac fate. One is a cytokine-based protocol (Fig. 1A) and the other uses small molecules to manipulate the WNT pathway (CHIR protocol, Supplemental Fig. 2B). In our study, we used the CHIR protocol only for experiments in Supplemental Figure 2B-E. Since our data implicated BMP and WNT as mediators of the GATA6-dependent program, we did this mainly to confirm that the phenotype we observed with the cytokine-based protocol was not biased by the differentiation protocol. However, we found the CHIR protocol to be overall relatively inefficient for cardiac differentiation using the parental H1 hESCs and the various isogenic lines. The in vitro cardiac differentiation protocols for hPSCs are known to be variable depending on lines and sometimes require extensive optimization for various media components and concentrations, cell seeding densities, and batch variations for crucial reagents. The cytokine-based protocol we optimized worked most efficiently with our hPSC lines to generate cardiomyocytes, therefore we committed to using it for the bulk of experiments in this study.</p><disp-quote content-type="editor-comment"><p>(2) The authors should characterise the mesodermal identity and cardiomyocyte subtypes generated with the activin/BMP-induction protocol thoroughly and clarify whether defects in the expression of BMP and WNTrelated gene affect the formation of specific cardiomyocyte subtypes in a chamber-specific manner. This analysis is important, as Sharma et al. suggested a role for GATA6 in orchestrating outflow tract formation, and Bison et al. similarly identified decreased expression of NRP1, a gene involved in outflow tract septation, in their GATA6 mutant cells.</p></disp-quote><p>We agree it is important that the mesodermal identities are quite thoroughly characterized.</p><p>For example, Fig. 2 (K+P+, Brachyury, EOMES), Fig. 3G&amp;H (lateral mesoderm, cardiac mesoderm RNAseq &amp; GSEA comparing datasets from Koh et al.). The capacity of the cytokine-based protocol to generate both FHF and SHF derived sub-types has been rigorously evaluated by Keller and colleagues, which we now cite (Yang et al. 2022). Since the null cells do not generate CMs, chamber specific subtypes cannot be evaluated; whether the GATA6 heterozygous mutants are biased is an interesting question. Indeed, the top GO term identified by CUT&amp;RUN analysis for GATA6 at day 2 of</p><p>differentiation is outflow tract morphogenesis, which is consistent with the interpretation by Sharma et al., but implicates this program at a much earlier developmental stage, long before cardiomyocyte differentiation. We think this is one of the most important findings of our study and appreciate the chance to highlight this in the revision (p. 9, 17). When we evaluated chamber-specificity for differentiated cardiomyocytes, we did not find significant differences, as indicated for the reviewer in the panel below (day 20 of differentiation). Since our study focuses on early stages of progenitor specification rather than cardiomyocyte differentiation, we agree that a more rigorous analysis would be of value, and indicated this as a limitation of our current study (p. 18).</p><fig id="sa4fig1" position="float"><label>Author response image 1.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100797-sa4-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>(3) The authors developed an iPSC line derived from a congenital heart disease (CHD) patient with an atrial septal defect and observed that these cells generate cTnnT+ cells less efficiently. However, it remains unclear whether atrial cardiomyocytes (or those localised specifically at the septum) are being generated using the activin/BMP-induction protocol and the patient-derived iPSC line.</p></disp-quote><p>As indicated above, our study is focused on cardiac progenitor specification, and we found similar differences with the patient-derived iPSC-CMs compared to using hESC heterozygous targeted mutants. While we did not note any major differences in expression of cardiomyocyte markers, whether the mutants show any biases toward sub-types of cardiomyocytes is an interesting question to be pursued in subsequent work.</p><disp-quote content-type="editor-comment"><p>(4) The authors should also justify the necessity of using the patient-derived line to further analyse GATA6 function.</p></disp-quote><p>This is a good point, and as suggested we provided the justification (p. 5-6). This is the first patient-derived iPSC line published with a heterozygous GATA6 mutation along with an isogenic mutation-corrected control generated for cardiac directed differentiation. Patients with congenital heart disease (CHD) associated with GATA6 mutations are typically heterozygous (also true for many other CHD variants; presumably homozygous null embryos would not survive). It is important to query if phenotypes found using targeted mutations in hESCs (or iPSCs) model the human disease, since the patient cells (or the hESCs) likely have additional genetic variants that might interact with the GATA6 mutation. The fact that both types of heterozygous cells (patient-derived iPSCs and targeted hESCs) generate similar defects in CM differentiation provides evidence supporting the use of these human cellular models to study the genetic and cellular basis for congenital heart disease. This is particularly important, since other models, such as heterozygous mice, do not show such phenotypes.</p><disp-quote content-type="editor-comment"><p>(5) Figure 3 suggests an enrichment of paraxial mesoderm genes in the context of GATA6 loss-of-function, which is intriguing given the well-established role of GATA6 in specifying cardiac versus pharyngeal mesoderm lineages in model organisms. Could the authors expand their analysis beyond GO term enrichment to explore which alternative fates GATA6 mutant cells may acquire? Additionally, how does the potential enrichment of paraxial mesoderm, rather than pharyngeal mesoderm, relate to the initial mesodermal induction from their differentiation protocol? Could the authors also rule out the possibility of increased neuronal cell fates?</p></disp-quote><p>We need to interpret our in vitro differentiation data cautiously in relation to what has been shown in vivo, since we are unlikely to be reproducing all the complex signaling taking place in the embryo. Yet we do see modest increases in gene expression levels including signatures of paraxial mesoderm and ECM/mesenchymal at days 2 or 3 of differentiation in the GATA6 mutant cells. Therefore, we now include a heatmap showing enriched paraxial mesoderm gene expression in the mutant cells, new Fig. 3I (see page 10).</p><p>A caveat of this result is that the cells are being differentiated toward cardiac fate, so a bias for alternative fates might be suppressed. We modified the protocol to favor paraxial fate by adding CHIR at day 2 (rather than XAV) and performing qPCR assays at day 3. We found this successfully induced paraxial mesoderm gene expression, but equally comparing wildtype, heterozygous, or null cells, so do not feel it warrants highlighting further.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewing Editor (Recommendations for the authors):</bold></p><p>Incorporation of marker analysis for various stages of iPSC to CM differentiation (mesoderm, cardiac progenitor, CM subtypes) would increase the significance and support for the findings presented. Further data on the link (direct or indirect) between GATA6 and Wnt/BMP signalling would also add to the significance of this study. A number of textual changes/clarifications are also suggested to improve the manuscript.</p></disp-quote><p>We appreciate the feedback and provide responses for issues raised for markers, direct or indirect interactions, and textual changes/clarifications in the following sections. As indicated above, we did not find obvious alterations in cardiac subtypes, but since our study is focused on early progenitor specification, this is an interesting question that we think should be more rigorously evaluated in subsequent work.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations for the authors)</bold>:</p><p>Minor details:</p><p>(1) On p6 &quot;Principal component analysis (PCA) showed that the cells derived from each genotype were well separated from each other (Supplemental Figure 2C)&quot;. All genotypes should be in one PCA plot to better evaluate the three genotypes.</p></disp-quote><p>We prepared the new plot as suggested, presented as new Supplemental Fig. 2C.</p><disp-quote content-type="editor-comment"><p>(2) p10: &quot;Chia et al.22 and found a significantly decreased enrichment in GATA6-/- cells relative to WT at day 2&quot; decreased enrichment of what? Direct target genes?</p></disp-quote><p>Thank you for catching this. Yes, the text was changed to indicate a “decreased enrichment in GATA6-/- cells relative to WT at day 2 for putative direct GATA6 target genes.”</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>Overall, this is an interesting study that addresses the early developmental roles of GATA6 on cardiac differentiation. While the identification of Wnt and BMP pathway genes to be involved in GATA6 regulation is not entirely unexpected, the authors do bring forth some useful knowledge that helps to further elucidate the mechanism of pre-cardiac mesoderm regulation. Some suggestions for improvement are included below -</p><p>Major points:</p><p>(1) Since the loss of Gata6 in this study is global (either as heterozygous or homozygous, it is likely that the very early requirement of Gata6 (e.g. mesodermal stage of differentiation)) is responsible for the cardiac transcriptional phenotype observed and not due to specific role of Gata6 in the cardiac lineage which would need to be addressed using conditional knock out of Gata6 in hPSC model. The authors should be more explicit when discussing the results as disruption of mesodermal differentiation leading to loss of downstream cardiac lineage cells. For example, I would change the title &quot;GATA6 loss-of-function impairs CM differentiation&quot; to &quot;GATA6 loss-of-function impairs mesodermal (or mesodermal lineage) differentiation&quot; and show the changes in cardiac progenitor cells genes (Isl1, Tbx1, Hand1, and BAF50c/Smarcd3) in addition to cardiomyocyte genes but no change in mesodermal (e.g. Brachyury, T, Eomes, Mesp1/2, etc) genes.</p></disp-quote><p>We agree with the reviewer’s interpretation. The title for the section was changed as suggested. In Fig. 1, we show changes in cardiac progenitor cell genes (Isl1, Hand1, and BAF50c/Smarcd3) while not seeing changes in mesodermal genes in Fig. 2 (e.g. Brachyury, Eomes, Mesp1/2). We note that the defect may be specific to cardiac (or anterior lateral) mesoderm, as the ability to express paraxial mesoderm markers was not impaired.</p><disp-quote content-type="editor-comment"><p>(2) The use of NKX2.5, TBX5, TBX20, and GATA4 as markers for CPC is not ideal. These markers are also expressed in differentiated cardiomycytes. ISL1 or TBX1 for second heart field progenitors and HAND1 or BAF60c/Smarcd3 for first heart field progenitors would be ideal.</p></disp-quote><p>As suggested, we included additional day 6 qPCR panel (new Fig. 1E) to evaluate the heart field progenitor markers.</p><disp-quote content-type="editor-comment"><p>(3) Much of the findings described in this study have been known in the field including the requirement of Wnt and BMP to induce mesodermal and subsequently cardiomyocyte differentiation. The key new information here is that Gata6 knockout disrupts Wnt and BMP signaling. It would help to further validate experimentally some of the Wnt and BMP genes as either direct or indirect targets of Gata6 using reporter assays.</p></disp-quote><p>While reporter assays are feasible and do provide relevant outputs, we feel that the use of any one or even several response elements in a reporter assay adds relatively little value compared to comprehensive analysis of bona fide network components. To address the reviewers concern we have included profiling heat maps for WNT and BMP pathway components to more rigorously and specifically evaluate the disruption in the signaling networks caused by loss of GATA6. Proving direct targets of endogenous genes is challenging, but we mapped many binding peaks for GATA6 to putative enhancers of WNT/BMP pathway genes (based on histone marks). We provide a list of these genes (new Fig. 4F) and distinguish these from WNT/BMP pathway genes that were not bound by GATA6 yet are down-regulated in the GATA6 mutant cells and are likely to be indirect targets (p. 12).</p><disp-quote content-type="editor-comment"><p>Minor points:</p><p>(1) Figures 1 and 2 - in the figure legend the labels w2, w4, m2, m5, m11, and m14 should be explained as the name of the clones of targeted hESC.</p></disp-quote><p>The legends were edited to provide this information.</p><disp-quote content-type="editor-comment"><p>(2) Supplemental Figure 3A - the resolution of the FACS plot is suboptimal.</p></disp-quote><p>We apologize and have corrected the plot resolution in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>(3) Supplemental Table 1 - it's intriguing that amongst all the SWI/SNF factors, the one that is known to be cardiac-specific (SMARCD3) did not come up in the GATA6-RIME-enriched proteins. Is this a reflection of the early stage in which GATA6 plays a role in development (e.g. mesendoderm development but not precardiac mesoderm development when SMARCD3 is expressed)?</p></disp-quote><p>We agree and have noted this feature in the revised manuscript (p. 17). We note that SMARCD3 is expressed in the RNA-seq data as early as day 2. Although speculative, it may be that GATA6 primarily interacts with SWI/SNF complexes prior to the role for SMARCD3 in cardiac specification.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations for the authors):</bold></p><p>(1) Figures 3G and 3H, as well as others, have resolution issues. The gene names are unreadable, and higherresolution images should be provided.</p></disp-quote><p>We apologize for the resolution issues and these have been fixed in the revised version.</p><disp-quote content-type="editor-comment"><p>(2) In their early manipulation of the WNT and BMP pathways (Figure 6A), it is unclear whether the activin/BMP protocol shown in Figure 1A was used. If this is the case, the authors should compare their results to a wild-type + DOX EV condition for consistency.</p></disp-quote><p>We clarified in the revision (Fig. 6A) that all the experiments in Fig. 6 use the cytokine protocol. In the revised figure, we included the wild-type + DOX EV condition as suggested.</p><disp-quote content-type="editor-comment"><p>(3) In Figures 6C and 6D, the authors should include an analysis of a wild-type isogenic line under their new CHIR/LB condition for comparison.</p></disp-quote><p>As suggested, we included the WT isogenic line in the comparison. For Fig. 6C these are shown on a separate graph because the Y-axis values are very different. Note that the CHIR/LB treatments that improve mutant cell differentiation impact the WT cells in the opposite manner.</p></body></sub-article></article>